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Abstract 
 
Gliomas are the most common tumors of the central nervous system. Our lab 
recently identified mutations in IDH1 and IDH2 as occurring frequently in progressive 
gliomas. We applied a series of biochemical and genetic approaches to explore the roles 
of the mutations in tumors and generate models for study.  
IDH1/2 normally function to convert isocitrate to α-ketoglutarate while 
simultaneously converting NADP+ to NADPH. To assess changes in metabolism, we 
completed metabolic profiling and complementary studies in cell lines with and without 
mutant IDH1 or mutant IDH2. We identified a decrease in hypoxia signaling and a 
decrease in global 5-hydroxymethylcytosine levels in cell lines with mutant IDH1/2. 
Having observed mutations in IDH1/2 in a large fraction of progressive gliomas, 
we asked if the mutations were either 1) advantageous for growth in brain parenchyma, 
or 2) advantageous in a particular cell-of-origin. Sequencing of a series of metastases to 
the brain from non-central nervous system tumors identified no mutations in IDH1/2, 
lending less credence to the first hypothesis. To elucidate whether mutations in IDH1/2 
can initiate glioma progression and explore the potential cell-of-origin for progressive 
gliomas, we generated mice in which we induced expression of mutant IDH2 in various 
populations of cells in the brain, either alone or in combination with TP53 deletion, 
another frequently altered gene in progressive gliomas. Mice with broad expression of 
mutant IDH2 developed hydrocephalus and encephalomalacia early in life, but did not 
develop tumors. Therefore, we restricted expression, and two brain tumors were 
identified in mice with both IDH2 mutation and TP53 deletion. While this suggests that 
both mutations might be required for the development of tumors, this is too small a 
number to draw significant conclusions. Further research with an expanded cohort of 
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mice, utilization of additional drivers of expression, and further characterization of 
identified tumors will help in elucidating the role of mutant IDH2 and the cell-of-origin for 
progressive gliomas. 
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1. Alterations in Gliomas 
 
1.1. Genetic Alterations in Astrocytomas 
 
Astrocytomas are the most common neoplasms of the central nervous system. 
Their name is derived from their appearance to astrocytes, cells in the brain that serve a 
wide variety of functions, including regulating signaling molecules between neurons. 
Astrocytomas are categorized as grade I-IV tumors using the 2007 WHO classification 
system4 based on histological appearance and historical survival. Histological grading is 
based on features such as the presence or absence of nuclear atypia, mitotic activity, 
vascular proliferation, endothelial hyperplasia, and necrosis. Genetic studies have 
identified a number of genetic alterations and mutations that correlate with various types 
and grades of tumors (Table 1). 
Pilocytic astrocytomas are the lowest grade astrocytomas, and do not progress 
to higher-grade tumors. These tumors occur largely in children and adolescents. 
Pilocytic astrocytomas are genetically distinct from higher-grade tumors. Among the 
most frequent changes is gain of copy number at 7q34,5 occurring in over two-thirds of 
pilocytic astrocytomas. Genetic studies have led to the identification of frequent gene 
rearrangement or mutation of BRAF,6 leading to constitutive activation of BRAF. 
  
   
(based in part of Brain Tumors, ELS 2011)3 
  2 
Table  1:  Common  Genetic  Abnormalities  in  Astrocytomas.  
Tumor	  and	  WHO	  
grade	   Chromosomal	  abnormality	   Genetic	  alteration	  
Grade I 
Pilocytic Astrocytoma 7q34 amplification BRAF/KIAA fusion 
Grade	  II	  
Diffuse	  Astrocytoma	  
–17p13.1	   TP53	  mutation	  
	  	  
Overexpression	  
	  
Mutation	  
	  
PDGFR	  
	  
ATRX	  
	  
	  	   Mutation	   IDH1/2	  
Grade	  III	  
Anaplastic	  
Astrocytoma	  
–9p21	   CDKN2A	  deletion	  
	  	   –13q	  
	  
RB1	  mutation	  
	  
	  	   –17p	  
	  
TP53	  mutation	  
	  
	  	  
Overexpression	  
	  
Mutation	  
	  
EGFR	  
	  
ATRX	  
	  
	  	   Mutation	   IDH1/2	  
Grade	  IV	  
Secondary	  
Glioblastoma	  
–17p	   TP53	  mutation	  
	  	   –10q23-­‐25	  
	  
PTEN	  mutation	  (rare)	  
	  
	  	  
–19q	  
	  
Mutation	  
	  
Unknown	  
	  
ATRX	  
	  
	  	   Mutation	   IDH1/2	  
Grade	  IV,	  Primary	  
Glioblastoma	   –9p21	   CDKN2A/B,	  ARF	  deletion	  
	  	   –10q23-­‐25	   PTEN	  mutation	  
	  	   .+7p	  
EGFR	  and/or	  EGFR	  
variant	  III	  amplification,	  
Sec61	  
	  	   Protein	  hyperexpression	   EGFR	  hyperexpression	  
PGDFR: platelet derived-growth factor receptor; EGFR: epidermal growth factor 
receptor 
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Unlike pilocytic astrocytomas, diffuse astrocytomas (WHO grade II) occur 
predominantly in adult patients in their third to fourth decades of life. Diffuse 
astrocytomas are slow-growing, diffusely infiltrating neoplasms. Histologically, diffuse 
astrocytomas comprise cells with an astrocytic appearance, which exhibit well-formed 
fibrillar processes and mild nuclear atypia.7 Unlike higher-grade gliomas, diffuse 
astrocytomas do not contain features associated with aggressive tumors, such as mitotic 
figures, endothelial hyperplasia, and necrosis.  Anaplastic astrocytomas (WHO grade III) 
are diffusely infiltrative tumors. Over time anaplastic astrocytomas almost universally 
progress to a higher grade tumor. 
Grade IV astrocytoma is the highest grade astrocytoma and also referred to as 
glioblastoma multiforme (GBM). GBMs can be subdivided into primary and secondary 
GBM. Primary GBM appears de novo, with no prior history of a lower grade astrocytoma. 
It is the most common form of GBM, representing over 90% of GBMs.7 Secondary GBM 
develops following a prior diagnosis of a lower grade astrocytoma, which progressed 
over time to GBM.7 Despite a similar histopathology, primary and secondary GBM each 
comprise a distinct combination of genetic changes and tend to occur in distinct 
populations. While patients with primary GBM are usually over 60 years old, patients 
with secondary GBM average 45 years of age at diagnosis.8 Combined, Grade II, Grade 
III, and secondary Grade IV astrocytomas are collectively referred to as progressive 
astrocytomas, and are distinct from primary GBM. 
The importance of understanding the genetic differences in GBM tumors from 
different patients is becoming increasingly clear, as genetic differences between tumors 
may more accurately predict prognosis than histological differences alone.9,10  
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Genetically, a series of mutations are commonly associated with progressive 
astrocytomas, the most common being mutations in isocitrate dehydrogenase 1 (IDH1) 
at residue 132 or isocitrate dehydrogenase 2 (IDH2) at the analogous residue R172; 60-
90% of diffuse astrocytomas have mutations in one of these genes.11-19 As with Grade II 
astrocytomas, mutations in IDH1R132 or IDH2R172 are identified in 60-90% of Grade III 
astrocytomas, making this the most common genetic abnormality identified in these 
tumors. These mutations will be discussed in further detail later. 
In progressive astrocytomas, the number of mutations increases as tumor grade 
increases. This may be associated with increased aggressiveness and the observed 
lower survival rates as tumor grade increases. Mutations or alterations in the Rb1 
pathway (Figure 1) increase with tumor grade.20-22 Although rare in Grade II 
astrocytomas, homozygous deletion of CDKN2A, homozygous deletion of RB1, or 
amplification of CDK4 is present in one third of Grade III astrocytomas and two thirds of 
Grade IV astrocytomas (GBM).21  
The CDKN2A locus is frequently deleted in a homozygous manner in progressive 
astrocytomas. 10-25% of anaplastic astrocytomas20,21,23 and 38-52% of GBM tumors (not 
divided by type) have homozygous deletion of this locus.20,21,23,24 Tumors with 
heterozygous deletion often have a mutation on the remaining CDKN2A locus, thus still 
inactivating the gene.20,21,23,24 Frequently, secondary GBMs with deletion of this locus do 
not demonstrate the deletion in the corresponding lower grade tumor.25 These results 
suggest that there is a strong selective pressure for deletion or inactivation of this region, 
and that this inactivation may be associated with tumor progression. 
Rates of loss of heterozygosity (LOH) at the RB1 locus increase with tumor 
grade and are associated with Grade IV glioblastomas,20,21 being present in 
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approximately 45% of all GBMs.21,26 However, other alterations are observed more 
frequently in lower grade tumors; CDK4 amplification is present in 8% of anaplastic 
astrocytomas20 and 6-34% of GBM tumors.20,22,24,27,28 Amplification of CDK4 occurs in 
about half of GBM samples without CDKN2A deletion.22 Mutations of RB1 or CDKN2A, 
and amplification of CDK4 are often mutually exclusive.20,27 
 
 
Figure  1:  TP53  and  Rb  pathways  
 
 
(reprinted  with  permission)3  
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Other mutations commonly identified in progressive gliomas include mutation 
and/or deletion of tumor	  protein	  p53 (Li–Fraumeni	  syndrome) (TP53).29 Mutations in TP53 
tend to cluster around the DNA binding domain24 and appear to be an early event in 
secondary GBM; a study of low-grade astrocytomas identified TP53 mutations in 65%-
75% of low-grade astrocytoma (Grade II) samples.20,30 In addition, one study found that 
for each secondary GBM containing TP53 mutations, the corresponding lower grade 
astrocytoma also contained the same mutation.25 Interestingly, although mutations in 
TP53 occur in approximately 60% of secondary GBM,8,31 their frequency is much lower 
in primary GBM, occurring in approximately 30% of primary GBMs.8,20,24,31-35 Although 
primary GBMs do not frequently have mutations in TP53, they often have mutations in 
other genes in the same pathway, with 60-70% of GBM having mutations somewhere in 
the p53 pathway24,32 (Figure 1). 
In various studies of brain tumor samples, up to 27% of Grade III astrocytomas or 
GBMs contained mutations in PIK3CA.24,32,36-39 PIK3CA is a subunit of PI3K, and its 
activation leads to increased cell proliferation, survival, and migration. Activating PIK3CA 
mutations have been found to occur more often in younger patients with high-grade 
astrocytomas; this population also has a higher frequency of secondary than primary 
GBM.37 It is likely that PIK3CA mutations tend to occur secondarily in the development of 
glioblastoma, rather than as an initiating factor.37 Additionally, although PTEN loss is 
identified in a significant fraction of primary GBMs, it is rarely seen in lower grade 
astrocytomas.40,41 
Mutations in alpha-thalassemia/mental retardation X-linked (ATRX ) were 
recently identified in approximately 7% of GBM.42 Further studies identified mutation in 
ATRX in over half of progressive astrocytomas of all grades,43,44 suggesting that this 
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may be a key feature of progressive gliomas. Interestingly, a majority of 
oligoastrocytomas (tumors with a mixed histology sharing features of both astrocytomas 
and oligodendrogliomas) also demonstrate mutations in ATRX, although 
oligodendrogliomas do not.43,44 Mutations in ATRX occur largely in tumors with IDH1/2 
mutations and TP53 mutations.43,44  ATRX was first found to play a role in pancreatic 
tumors and, in these tumors, led to alternative lengthening of telomeres.42 It appears that 
ATRX may play a similar role in gliomas.43,45 
Overexpression of platelet-derived growth factor A (PDGFA) and its receptor is 
also a common feature in progressive astrocytomas.46 Although PDGF is only 
occasionally amplified,24 PDGF and its receptors are upregulated in progressive gliomas 
and primary GBM at a high frequency, increasing with tumor grade.47-50 Of note, 
overexpression of PDGFRα is correlated with TP53 mutation.30 
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Figure  2:  Proposed  progression  of  gliomas.  
  
 
Although there is great heterogeneity in the individual genes mutated in different 
primary GBMs, the actually pathways affected by these mutations are actually rather 
limited, with most mutations occurring in genes involved in receptor tyrosine kinase, p53, 
and retinoblastoma pathways24,32 (some common mutations are listed in Figure 2). While 
an individual tumor has multiple mutations, these mutations are often in different 
pathways, with over two-thirds of tumors demonstrating mutations in all three 
pathways.24,32  
 
(reprinted  with  permission)3  *TP53  
mutation  is  present  in  approximately  30%  of  primary  GBM,  but  over  60%  of  progressive  
astrocytomas.  
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1.2. Expression Studies in Gliomas 
 
Expression analyses have identified 3-6 distinct expression patterns in GBM.51-53 
These fall largely into three main groups: proneural, proliferative, and mesenchymal 
(referred to by different names in different articles). The proneural group is characterized 
by the upregulation of genes involved in either Notch signaling, platelet derived growth 
factor signaling, the ARF pathway, or the TEL pathway.52 The proneural group also 
shows expression of genes associated with neural stem cells or transit-amplifying cells,51 
and tumors in this group have a high frequency of mutations in IDH1.53 Lower grade 
tumors (not Grade IV) fall almost exclusively into the proneural group.51,52 The proneural 
group also comprises patients of a younger age compared to the proliferative and 
mesenchymal groups.51,52 Additionally, patients in the proneural group, regardless of 
grade, have an improved survival compared to patients with tumors characterized as 
proliferative or mesenchymal. Interestingly, in some cases, as tumors in the proliferative 
group progress, they gain a more mesenchymal profile.51 
The proliferative group is characterized by the expression of genes involved in 
cell cycle regulation and proliferation.51,52 The mesenchymal group is characterized by 
overexpression of genes involved in angiogenesis, the NF-κB pathway, and the tumor 
necrosis factor pathway.51-53 Both the proliferative and the mesenchymal groups have 
decreased PTEN expression and increased AKT compared to the proneural group.51  
These expression signatures may provide some insight into the tumor cell of 
origin based on their similarities to the expression signatures of normal tissues. The 
proneural group shares similarity to some neural stem cell lines,51,52 while proliferative 
tumors shared similar profiles with hematopoietic stem cells and the Jurkat cell line, 
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while the mesenchymal group shared features with a host of normal tissues, including 
endothelial and dendritic cells.51 
 
1.3. Genetic Alterations in Oligodendrogliomas  
 
Oligodendrogliomas are a form of progressive glioma and histologically comprise 
cells resembling oligodendrocytes. Oligodendrogliomas are divided up by grade into 
well-differentiated oligodendrogliomas (WHO grade II) and anaplastic 
oligodendrogliomas (WHO grade III).7 Like progressive astrocytomas, over 80% of 
oligodendrogliomas contain mutations in either IDH1 or IDH2.12 Oligodendrogliomas also 
have characteristic losses of chromosomes 1p and 19q in over two-thirds of samples.54-
57 This distinguishes them from astrocytomas genetically (Table 2). Correspondingly, 
oligodendrogliomas generally do not contain mutations in TP53.58  
Until recently, it was unclear which genes were the key drivers for the 
exceedingly frequent loss of chromosome arms 1p and 19q in oligodendrogliomas. 
Recent research suggests that the genes may be homolog of capicua (CIC) and far-
upstream element binding protein 1 (FUBP1).58 Over two-thirds of tumors with 19q 
deletion had mutations in CIC,58-60 and over half of oligodendrogliomas as a group had 
mutations in CIC.43 CIC appears to play a role in receptor tyrosine kinase signaling.61,62 
While FUBP1 mutations were not as frequent as CIC alterations, mutations in FUBP1 
were identified in over 10% of oligodendrogliomas in multiple studies.43,58-60 FUBP1 
appears to play a role in myc signaling.63 However, more research is needed to better 
understand the roles mutations in these genes may be playing in oligodendrogliomas. Of 
note, all tumors with mutations in CIC or FUBP1 had mutations in IDH1 or IDH2.43 
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Recently, ATRX was also identified as mutated in a fraction of central nervous 
system tumors, as described previously.64 Interestingly, 7-14% of oligodendrogliomas 
contained mutations in ATRX.42,43 
The exceedingly high rate of mutations in IDH1/2 in both progressive gliomas 
and oligodendrogliomas strongly suggests that mutations in these genes may be among 
the earliest changes in a common precursor cell that gives rise to both tumor types 
(Figure 2).  
 
Table  2:  Summary  of  Genetic  Alterations  in  Oligodendrogliomas  
Tumor	  and	  WHO	  grade	   Chromosomal	  abnormality	   Genetic	  alteration	  
Grade	  II	  
Oligodendroglioma	  
Mutation	  
	   IDH1/2	  
	  	   –1p	  –19q	  
FUBP1	  
CIC	  
Grade	  III	  	  
Anaplastic	  Oligodendroglioma	  	   Mutation	   IDH1/2	  
	  	   Mutation	   PIK3CA/PIK3R1	  
	  	   –1p	  –19q	  
FUBP1	  
CIC	  
	  	   –9p	   CDKN2A	  deletion	  
	  	   –4,	  –14,	  –15,	  –18	   Unknown	  
	  	   –10q	   PTEN	  (rare)	  	  
 
Chromosome 9p losses in oligodendrogliomas correlate with grade. PTEN gene 
mutations and homozygous deletions of CDKN2A/B are not found in well-differentiated 
oligodendrogliomas but are found in up to half of anaplastic oligodendrogliomas.65 
Studies have also identified frequent mutations in either PIK3CA or PIK3R1 in a 
significant fraction of anaplastic oligodendrogliomas.37,58 
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1.4. Mouse Models of Progressive Gliomas 
 
Models in mice have begun exploring the interplay between genes, and which 
mutations are sufficient alone or in combination with others to form gliomas. For 
example, TP53 null mice do not form spontaneous brain tumors.66-68 Interestingly, 
sometimes a targeted deletion leads to tumor formation. In one study 17% of GFAP-
Cre/TP53fl/fl mice developed gliomas resembling Grade III astrocytomas.34 Additionally, 
when TP53 deletion is combined with other mutations, this often either leads to tumor 
formation or accelerates it. For example, when GFAP-Cre/TP53fl/fl mice also had 
PTENfl/wt, tumors formed at a much higher rate than with TP53 deletion alone.34 
Interestingly, the driver used for different mutations is critical to whether or not 
tumors form. Mice overexpressing PDGFB driven by GFAP do not develop GBM,66 
although PDGFB overexpression driven retrovirally often leads to the formation of brain 
tumors.68,69 The combination of a TP53 null mice with either PDGFB overexpression 
retrovirally or PDGFB overexpression driven by a GFAP driver led to high rates of tumor 
formation.68 Interestingly, PDGFB injected retrovirally and activated in cells with Nestin 
promoters generated oligodendrogliomas, whereas the same gene driven by GFAP 
promoters also generated oligoastrocytomas,68 thus emphasizing the importance of the 
cell-of-origin in the type of tumors which form, even with the same genetic mutations. 
The aforementioned model is one of the few models to incorporate mutations/alterations 
frequently observed in progressive gliomas, as opposed to mutations/alterations 
frequently observed in primary GBM. 
Models of low-grade gliomas have been developed, utilizing mice with 
heterozygous germline deletion of both TP53 and NF1.70 Both these mice and mice with 
heterozygous germline TP53 deletion and GFAP driven NF1 deletion demonstrate 
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GFAP+ astrocytomas of all grades.70,71 These tumors occurred in locations throughout 
the brain, including the olfactory bulb, cortex, and brainstem.70,71 An additional study that 
added heterozygous PTEN deletion to the NF1/TP53 deficient mouse model found faster 
formation of GBM tumors and survival of one week vs. the eight weeks seen in the 
original study with intact PTEN.72 
These studies provide an insight into the complexities of studying gliomas 
utilizing genetically-engineered mouse models. Different combinations of mutations can 
lead to tumors that are histologically identical. On the other hand, the same mutations, 
induced using a different driver impacting a slightly different population of cells, can lead 
to the development of a different type of tumor. In some cases, the same mutation may 
lead to tumors when present in one type of cell, and not lead to any tumors when driven 
in another type of cell. While this may be perceived as a challenge of using mouse 
models, it is also an opportunity; studying multiple models may allow us to better 
understand the conditions that promote the growth of tumors. 
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2. Isocitrate Dehydrogenase and Human Disease 
 
2.1. Isocitrate Dehydrogenase and Progressive Gliomas 
 
Our understanding of progressive gliomas was radically altered with the 
discovery of mutations in IHD1 and IDH2.32 These mutations were first identified in a 
study sequencing over 20,000 protein-coding genes in a series of glioblastoma samples, 
which revealed the presence of mutations in IDH1 at the codon for amino acid residue 
132 in 12% of GBMs.32 These mutations were striking because they all occurred in the 
same amino acid residue, arginine 132, and were associated with younger patients who 
had a longer survival.12 A series of follow-up studies of gliomas led to the discovery of 
the presence of mutations in IDH1 in 60-90% of progressive gliomas, including grade II 
and grade III astrocytomas, oligodendrogliomas, and oligoastrocytomas, as well as 
secondary glioblastomas.11-13,15,16,73,74  In addition, progressive gliomas that did not have 
mutations in IDH1 were often found  to have mutations in IDH2 at the analogous amino 
acid residue R172.12 On the contrary, primary GBM only rarely had mutated IDH1/2.12 
IDH1 and IDH2 are homologous enzymes that function to catalyze the 
conversion of isocitrate to α-ketoglutarate while concomitantly reducing NADP+ to 
NADPH (Figure 4). To complete this reaction, isocitrate is first oxidized to 
oxalosuccinate, while reducing NADP+ to NADPH. Subsequently, oxalosuccinate is 
decarboxylated to generate α-ketoglutarate. Whereas IDH1 localizes to the cytosol and 
peroxisomes,75-77 IDH2 localizes to the mitochondria (Figure 3).78  
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Figure  3:  IDH  mutations  and  cellular  pathways.  
 
IDH1 and IDH2 normally function as homodimers in both humans and other 
organisms.79-81 Normally the arginines located at these mutation hotspot sites in IDH1/2 
interact with the β-carboxyl group of isocitrate;82,83 these mutations lead to a change in 
the active site of the proteins.84 The consequences of IDH1/2 mutations are two-fold. 
First, mutations in IDH1R132 and IDH2R172 lead to abrogation of wild-type activity, with a 
dominant negative effect on normal IDH1 or IDH2 activity.12,13,82 Secondly, these 
mutations lead to a novel function- namely, the conversion of α-ketoglutarate to D-2-
hydroxyglutarate (2-HG) and the oxidation of NADPH to NADP+ (Figure 4).83-85 
Subsequent studies have only found mutations in a single other amino acid, IDH2R140,83 
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A)  IDH1/2  normally  
function  to  convert  isocitrate  to  α-­‐‑ketoglutarate  while  generating  NADPH  from  
NADP+.  B)  When  mutated  in  gliomas,  these  enzymes  are  able  to  catalyze  a  new  
reaction,  converting  α-­‐‑ketoglutarate  to  2-­‐‑HG  while  oxidizing  NADPH  to  NADP+.  
which is also predicted to normally interact with the β-carboxyl group of isocitrate. When 
mutated, it also leads to accumulation of 2-HG.83 Nonetheless, the ramifications for the 
cell and the roles these mutations and the resulting novel metabolite play in the 
development of tumors are still being elucidated.  
 
Figure  4:  Normal  and  mutant  function  of  IDH1/2.         	  
	   	  
 
  
A. 
B. 
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2.2. IDH1/2 Mutations in Non-CNS Tumors 
 
IDH1/2 were recently identified as frequently mutated in acute myelogenous 
leukemias.86, and appear to inhibit hematopoietic differentiation and lead to a 
hypermethylation phenotype.87,88 They have also been identified in central and periosteal 
cartilaginous neoplasms.89 Less frequently, mutations have been identified in prostate 
cancer,73 some myelodysplastic syndromes,90 B-cell acute lymphoblastic leukemia,73 
blast phase chronic myelogenous leukemia,91 colorectal cancer,92 melanoma,1 breast 
carcinoma,93 and paraganglioma.94 
 
2.3. Oxidative Stress 
 
IDH1 has been shown to play a role in protection against reactive oxygen 
species (ROS) generated during metabolism or conditions of cellular stress in yeast and 
mammalian lines.95,96 Normal functions of NADPH are numerous, including synthesis of 
fatty acids and cholesterol, and a role in nucleotide synthesis (reviewed in 97). NADPH is 
also utilized by cells as a reducing equivalent for the generation of glutathione and 
thioredoxin, which help protect against oxidative damage.98,99 The brain, compared to 
other tissues, consumes a large amount of oxygen (reviewed in Ballatori et al.100), and 
thus may have an increased sensitivity to oxidative damage. Studies have shown that in 
fibroblast, leukemia, and other cell lines, increased IDH1 leads to an increase in the ratio 
of reduced glutathione to total glutathione101,102 and appears to provide protection 
against oxidative damage.96,103,104  
Decreases in cellular IDH1 levels have been shown to lead to decreased survival 
  18 
after oxidant exposure.96 This is correlated with increased levels of peroxides, lipid 
peroxidation, and DNA damage.96 Mutant IDH1/2, which actively utilizes NADPH to 
generate 2-HG, can thus potentially decrease levels of NADPH through its active 
depletion. 
Interestingly, studies using the addition of 2-HG in vitro to cerebral cortex lysates 
from young rats demonstrate an increase in oxidative stress and lipid peroxidation 
following addition of 2-HG.105 When taken in the context of the previous studies, it 
becomes apparent that there may be two different mechanisms through which mutant 
IDH1/2 may lead to increased oxidative stress- 1) a decrease in native IDH1/2 activity, 
reducing the capacity to respond to oxidative stress, and 2) an increase in 2-HG, which 
may inherently lead to increased oxidative stress.  
 
2.4. Hypermethylation 
 
Accumulation of 2-HG in tumors with mutant IDH1/2 and a potential decrease in 
α-ketoglutarate may interfere with α-ketoglutarate-requiring enzymes. Recent research 
has shown that TET2 function may be impaired in the presence of 2-HG.87,106 TET2 
normally functions to hydroxylate 5-methylcytosine to 5-hydroxymethylcytosine, and may 
work to actively demethylate DNA.107,108 In some leukemias, mutant IDH1/2 are 
correlated with a global hypermethylation phenotype and decrease in 5-
hydroxymethylcytosine.87 The same research on mutant IDH1/2 in leukemias has 
suggested that changes in methylation status correlate with a decrease in hematopoietic 
differentiation and the maintenance of a more undifferentiated state.87 Interestingly, 
recent studies have also found a correlation between IDH mutation status and global 
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hypermethylation in glioma patient samples.106,109,110 Studies are now beginning to 
elucidate genes for which there may be a correlation between promoter 
hypermethylation and presence of mutant IDH1, such as RBP1,110,111 GOS2,110 and 
MGMT.112-114 It seems reasonable to hypothesize that hypermethylation may be caused 
by inhibition of α-ketoglutarate dependent dioxygenases, such as TET2.87,106 However, 
one group has proposed the reverse; namely, that an initial hypermethylation phenotype 
(of unknown origin) may promote mutations in IDH1/2.110 
Mouse ES cells have an interesting methylation pattern, with globally elevated 5-
hydroxymethylcytosine levels, with 5-hydroxymethylcytosine primarily located at 
promoters with a high CpG content;115 5% of CpGs demonstrating hydroxymethylated 
cytosines.116 However, the role of 5-hydroxymethylcytosine in development is still not 
clear, with research providing conflicting results. In one study in mouse ES cells, genes 
with promoters with high 5-hydroxymethylcytosine were expressed at higher levels than 
genes with promoters with either high 5-methylcytosine or unaltered cytosine.116 As 
mouse ES cells were allowed to differentiate, the levels of 5-hydroxymethylcytosine 
decreased, and the expression of the genes associated with 5-hydroxymethylcytosine 
also decreased.116 However, another study found low expression of genes with elevated 
levels of 5-hydroxymethylcytosine at their promoters, but that 5-hydroxymethylcytosine 
was preferentially located at the promoters of genes that were likely to become 
upregulated during differentiation.115 This appeared to “prime” those genes for future 
activity.115 Thus, although it appears that 5-hydroxymethylcytosine plays a critical role in 
ES cells and differentiation, more studies are needed to elucidate the exact role. It is 
possible that 5-hydroxymethylcytosine may play different roles on different promoters 
depending on other cues, such as histone methylation status. Of note, both TET1 and 
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TET2 are expressed in mouse ES cells, and appear to play a role in differentiation.117 As 
these enzymes have been shown to be inhibited by 2-HG,87 the presence of TET 
proteins in mouse ES cells means that mouse ES cell lines may have some utility for 
studies on the effect of mutant IDH1/2 on 5-hydroxymethylcytosine levels. 
 
2.5. Hypoxia	  
 
Hypoxia is a common feature of the tumor microenvironment, and resistance to 
hypoxia is often considered a key feature of glial tumors. Hypoxia inducible factor-1α 
(HIF-1α), a key signaling molecule in hypoxia, plays a role in regulating apoptosis, 
metabolism, and angiogenesis (reviewed in118). Mutant IDH1/2, by modulating the HIF-
1α pathway, may impact oxygen sensing in the cell. Levels of HIF-1α are regulated by 
HIF prolyl hydroxylases (PHDs), which ubiquitinate HIF-1α, leading to its degradation. 
PHDs use α-ketoglutarate as a substrate. Thus, low levels of α-ketoglutarate, as is 
theoretically possible in the setting of mutant IDH1/2, might lead to an increase in HIF-1α 
signaling.119 Additionally, 2-HG has already been shown to inhibit TET2, an α-
ketoglutarate-dependent dioxygenases, and may inhibit other α-ketoglutarate 
dioxygenases, such as HIF-1α.82,106 Thus, mutant IDH1/2 have the potential to increase 
levels of HIF-1α via decreases in α-ketoglutarate or inhibition of PHD by 2-HG. 
Nonetheless, studies regarding the effect of mutant IDH1/2 on both α-
ketoglutarate and HIF-1α are conflicting in their results. While some studies have 
observed a decrease in α-ketoglutarate and an increase in HIF-1α in cell lines over-
expressing mutant IDH1,82,106 other studies have found no correlation between mutant 
IDH1 status and HIF-1α expression levels.120 Studies in patient tumors have also yielded 
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conflicting results.82,120 More studies are needed to better understand the impact of these 
mutations on hypoxia signaling. 
 
2.6. Mouse Models of Mutant IDH 
 
Recently, a mouse model was generated allowing for conditional expression of 
mutant IDH1R132H under the control of Cre.88,121 These mice were crossed with mice 
allowing for expression of Cre in either all hematopoietic progenitors or only myeloid 
progenitors.88 The researchers identified an increase over time in hematopoietic stem 
cells and myeloid progenitors in the bone marrow and spleen of both mouse models, 
and an increase in histone methylation.88 They then expressed IDH1R132H in the brain 
using either Nestin-Cre or GFAP-Cre.121 Both drivers led to broad expression within the 
brain in a large fraction of the cells. Nestin-Cre/IDH1R132H/wt mice died shortly after birth, 
and developed massive hemorrhage within the brain.121 These mice also demonstrated 
“cavitation” and significant cell death throughout the brain.121 GFAP-Cre led to a greater 
variability in degree of expression of mutant IDH1.122 Interestingly, in these mice, the 
degree of hemorrhage correlated with levels of 2-HG in the brain.121 Additionally, 
although neural stem cell and glial progenitor cells from these mice did not demonstrate 
an increase in histone methylation, they did demonstrate a decrease in presence of 5-
hydroxymethylcytosine.121 However, although these mice developed a wide variety of 
symptoms correlated with expression of mutant IDH1, these mice did not develop brain 
tumors.121 Further studies may yet identify a model in which mutant IDH1 may, either 
alone or in concert with other mutations, lead to the development of gliomas. To date, no 
genetically-engineered mouse models have been developed utilizing mutant IDH2. 
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2.7. Mutant IDH2 and 2-hydroxyglutaric Acidurias 
 
Patients with a rare disease known as D-2-hydroxyglutaric aciduria have 
elevated levels of D-2-HG in their urine123-126 and serum.124,125 Patients with D-2-
hydroxyglutaric aciduria have developmental delay and often develop an epileptic 
encephalopathy, in addition to hypotonia and dysmorphic features.123,127,128 MRI studies 
in various cases show decreased white matter and bilateral symmetrical lesions, 
sometimes referred to as subependymal cysts, adjacent to the lateral ventricles.123,125,129 
MRI studies have also shown dilated ventricles and cortical atrophy.124-126,129 
Interestingly, both macrocephaly124 and microcephaly125 have been noted. Post-mortem 
histological analyses were completed on one patient with 2-hydroxyglutaric aciduria. 
These studies confirmed bilateral white matter atrophy and corresponding enlargement 
of the lateral ventricles.126 There was loss of white matter fibers and mild gliosis.126 
Studies in model systems have attempted to begin to explore the mechanism behind this 
striking phenotype. When 2-HG is applied to neuronal cultures from chick embryos, 
extensive neurotoxicity is noted.130 These studies also identified an increase in 
intracellular calcium in neurons exposed to 2-HG, and that excitotoxicity from NMDA 
receptor activation and calcium influx may be a mechanism for neurotoxicity.130 Of note, 
although patients with L-2-hydroxyglutaric aciduria (in which the other chiral form of 2-
HG is elevated in urine and serum) have increased rates of a variety of brain tumors 
(reviewed in131), patients with D-2-hydroxyglutaric aciduria do not appear to be at 
increased risk of brain tumors. 
It has been identified that IDH1 and IDH2 normally generate 2-HG at low levels 
during normal function.132 About half of patients with D-2-hydroxyglutaric aciduria have 
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mutations in D-2-hydroxyglutaric acid dehydrogenase.128 This gene normally functions to 
convert D-2-HG, which has no known function in the human body, to α-ketoglutarate. It 
appears that without this gene, 2-HG accumulates at least in part from the normal 
function of IDH1/2, leading to the aforementioned symptoms.127 Although this provided 
an explanation for the source of D-2-hydroxyglutaric aciduria in approximately half of 
patients suffering from this disease, the cause of the increase in D-2-HG was unclear in 
the other half. Recently, a group identified mutations in IDH2 in the majority of these 
remaining patients.133 As a result, patients with 2-hydroxyglutaric aciduria are now 
classified into two groups: Type I patients have mutations in D-2-hydroxyglutaric acid 
dehydrogenase, and a comparatively moderate increase in 2-HG, whereas Type II 
patients have mutations in IDH2R140 and a higher increase in 2-HG in urine and serum 
compared to Type I patients.134 However, due to the small number of patients that suffer 
from 2-hydroxyglutaric aciduria, there is still much that is not understood about this 
disease. 
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3. Role of IDH1 in Tumor Location versus Cell Type 
(based on Lopez, et al.1) 
3.1. Introduction 
 
Although IDH mutations have been identified in gliomas and some leukemias, we 
attempted to address whether mutations in IDH may be present in other tumor types. In 
considering other tumors which might also harbor previously unknown mutations in 
IDH1/2, melanomas were considered, as they share some critical genetic features with 
progressive astrocytomas, such as a high rate of mutations in TP53.135 Although a 
previous small-scale study had not identified any mutations in IDH1 in melanomas,136 we 
decided to complete a larger and broader study utilizing 78 tumor samples and cell lines. 
Additionally, we attempted to address a second hypothesis with this study. In 
noting that both oligodendrogliomas and astrocytomas have IDH1/2 mutations while 
sharing very few other mutations in common between them, the hypothesis arose that 
there was potentially a characteristic of the brain parenchyma that placed a selective 
pressure for the presence of IDH1/2 mutations for growth within the brain. We attempted 
to address this hypothesis by assessing whether IDH1/2 mutations might be observed in 
metastases to the brain from non-central nervous system tumors. We sequenced 
IDH1R132 and IDH2R172  in 53 metastatic brain tumors, including melanomas. 
 
3.2. Methods 
 
We obtained a panel of cell lines derived from pathology-confirmed non-CNS 
metastatic melanoma tumor resections, with paired blood samples, from 78 patients 
enrolled in a clinical trial at the Surgery Branch of the National Cancer Institute at the 
1 
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United States National Institutes of Health, and approved by the appropriate Institutional 
Review Board. Tumor resections were mechanically or enzymatically dispersed to 
generate the cell lines. We also obtained a panel of 53 frozen tumor resections from 
metastases to the brain through the Tissue Bank at the Preston Robert Tisch Brain 
Tumor Center at Duke University. Genomic DNA was isolated using the DNeasy Blood 
and Tissue Kit (Qiagen, Valencia, CA, USA). Primers for sequencing were synthesized 
by Integrated DNA Technologies (Coralville, IA, USA) and Invitrogen (Carlsbad, CA, 
USA). Primers were designed to amplify Exon 4 of IDH1 or IDH2 using Primer 3 
(http://www-genome.wi.mit.edu/cgibin/primer/primer3_www.cgi), and generated products 
between 300-500 base pairs in length. Exon 4 contains the codon for the most frequently 
mutated amino acid residue in both IDH1 and IDH2 in gliomas. In one melanoma sample 
in which a mutation in IDH1 was identified, all coding exons of TP53, CDKN2A/B, as well 
as hotspot exons of BRAF and NRas, were sequenced using the aforementioned 
techniques. 
 
3.3. Results 
 
78 melanoma samples from patients were sequenced for IDH1R132 and IDH2R172 
mutations. A heterozygous IDH1 c.C394T (p.R132C) mutation was identified in tissue 
derived from a melanoma lung metastasis from a 53-year-old female , and was not 
present in corresponding blood (Figure 5). No IDH2R172 mutations were detected in any 
of these samples. BRAF, NRas, TP53, and CDKN2A/CDKN2B were sequenced in the 
sample with mutated IDH1. No mutations were identified in NRas, TP53, and 
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CDKN2A/CDKN2B. A BRAF c.T1799A (p.V600E) mutation, which is an activating 
mutation,137,138 was identified in this sample.  
 
 
Figure  5:  An  IDH1R132C  mutation  identified  in  a  cell  line  derived  from  a  
melanoma  metastasis  to  the  lung.  
 
We sequenced Exon 4 of IDH1 and IDH2 in 9 melanoma metastases to the brain 
and 44 other metastases to the brain from other primary tumors, including lung, breast, 
renal, uterine, ovarian, esophageal, and urothelial cancers. No mutations were identified 
in any of the tumor metastases.  
 
3.4. Discussion 
 
Mutations in IDH1 or IDH2 occur at a high frequency in progressive gliomas, 
acute myelogenous leukemias, and central and periosteal cartilaginous neoplasms.139 
Mutations are present at a lower frequency in some myelodysplastic syndromes90 and 
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blast phase chronic myelogenous leukemia91 However, these mutations are very rare in 
other tumors.73,91-94 Because melanomas share some similar genetic features to 
progressive astrocytomas, we decided to sequence a panel of melanomas in an attempt 
to evaluate the frequency of IDH1/2 mutations in these tumors. We identified an 
IDH1R132C mutation in one melanoma.1 To our knowledge, this is the first IDH1/2 
mutation identified in a melanoma. However, sequencing of a panel of melanomas did 
not identify further mutations in IDH1/2, suggesting that mutant IDH1/2 are unlikely to 
play a large role in the development of these tumors. 
Noting that mutations in IDH1/2 only occur at a high rate in progressive gliomas 
and acute myelogenous leukemias, we developed two potential hypotheses for this 
observation. Hypothesis 1: IDH1/2 mutations are cell-lineage dependent. In other words, 
there is some shared characteristic of the cell-of-origin for progressive gliomas and 
acute myelogenous leukemias, and these cells are inherently predisposed to malignant 
transformation in the presence of mutant IDH1/2. Hypothesis 2: There is a selective 
pressure within different niches within the body, including the brain parenchyma, and 
IDH1/2 mutations may promote growth in those tissues. If this second hypothesis were 
correct, then we would expect to see a higher rate of mutations in IDH1/2 in metastases 
to the brain from non-central nervous system tumors than in tumors at the site-of-origin. 
In our study, we did not identify any mutations in Exon 4 of IDH1/2 in a panel of 
metastases to the brain from non-CNS tumors. This would appear to disprove the 
second hypothesis, that IDH1R132 or IDH2R172 mutations provide a selective growth 
advantage in a general sense within brain tissue. Therefore, we conclude that of these 
two hypotheses, the first is more probable. In other words, we propose that mutations in 
IDH1/2 are likely advantageous in a cell-lineage dependent manner, and that there is a  
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selective pressure for mutations in the cell-of-origin for progressive gliomas and the cell-
of-origin for acute myelogenous leukemias. However, the scope of these studies does 
not allow us to rule out other hypotheses. For example, an unknown mutation may 
initiate the tumor, and provide selective pressure for subsequent mutations in IDH1/2. 
Further studies are needed to better understand the features shared by tumors with 
these mutations, and to comprehend the role mutant IDH1/2 may play in tumorigenesis. 
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4. Metabolic Profiling and Biochemical Characterization 
 
4.1. Introduction 
 
The Warburg effect,140 in which there is an increased rate of aerobic glycolysis, 
has been proposed as a potential result of changes in metabolism resulting from 
mutations in IDH1/2.141,142 The Warburg effect is particularly prominent in GBM, with one 
study finding that 90% of glucose and 60% of glutamine is converted into lactate and 
alanine in GBMs.143 Increased glycolysis may provide an advantage to a dividing cancer 
cell by providing not only energy but also basic metabolites required by a rapidly dividing 
cell.141 The effect of mutant IDH1/2 on the cellular metabolic and physiologic state is 
largely unknown. It is possible that mutations in IDH1 may provide a mechanism for 
initiating this shift in metabolism, by altering the levels of key metabolites needed in a 
rapidly growing cell, such as NADPH.142 Because these are among the earliest changes 
in progressive gliomas, it is possible that these changes occur in a precursor cell that is 
common to both oligodendrogliomas and progressive astrocytomas. A cell that is in a 
more undifferentiated state may have unique responses to the changes induced by the 
presence of mutant IDH1/2 compared to a more differentiated cell. We utilized broad 
metabolomics profiling in mouse ES cells with and without mutant IDH1 or mutant IDH2 
in hopes of identifying changes in metabolism and other pathways. 
Studies in leukemias suggest that 2-HG may inhibit the function of TET2, which 
normally functions to convert 5-methylcytosine in DNA to 5-hydroxymethylcytosine.87 
The generation of stable mouse cell lines expressing mutant IDH1/2 allowed us to 
directly evaluate the relationship between mutant IDH1/2 and methylation status in 
undifferentiated cells, which demonstrate a unique methylation pattern compared to 
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terminally differentiated cells.144 We addressed whether mutant IDH1/2 affects the 
methylation status of these cells.  
 
4.2. Methods 
 
4.2.1. Generation of Mouse ES Cell Lines with Conditional 
Heterozygous Expression of IDH1R132H or IDH2R172K 
 
To study the effect of mutations in IDH1/2 in undifferentiated cells, we utilized the 
UNC Animal Models Core to generate mouse ES cell lines with knock-in IDH1R132H or 
IDH2R172K. Plasmid-based gene targeting vectors were used. Following integration of 
homology regions into the vector, point mutations were inserted for IDH1R132H (codon 
132: CGA!CAC) and IDH2R172K (codon 172 AGG!AAG). The constructs also 
contained 3' and 5' homology arms for homologous recombination within the appropriate 
gene, a neomycin selection marker flanked by Flp sites, and a stop cassette (adenovirus 
splice acceptor and three copies of an SV40 polyadenylation sequence) flanked by Cre 
sites (Figure 6). The plasmid was electroporated into mouse ES cells for homologous 
recombination. Successful homologous recombination was verified at UNC via PCR and 
Southern blot (not shown). Heterozygosity was also verified through genomic 
sequencing. 
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                            Note  that  the  codon  for  IDH1R132  is  located  in  exon  3  of  IDH1,  
whereas  the  codon  for  IDH2R172  is  located  in  exon  4  of  IDH2.  Loxp  sites  are  denoted  by  
purple  triangles.  Flp  sites  are  denoted  by  orange  ovals.  
  
 
Figure  6:  Targeting  vector  for  homologous  recombination  allowing  for  
expression  of  mutant  IDH1/2.  
 
 
 
To generate mouse ES cells with stable endogenous expression of mutant 
IDH1/2, Cre-mediated deletion was used to remove the selection marker and stop 
codons.  
Presence of the mutant alleles of IDH1/2 was verified through sequencing of 
genomic DNA (gDNA). Isolation of gDNA was accomplished using Lyse and Go PCR 
Reagent (Thermo Scientific, USA) per the manufacturer’s protocols. The region of 
interest containing the mutation was amplified using KAPA Taq polymerase using the 
following primers. For IDH1: Forward: 
GTAAAACGACGGCCAGTTCACCAAAGATGCTGCAGAG, Reverse: 
GGGTGTAGATGCCCAAAGAA. For IDH2: Forward: 
GTAAAACGACGGCCAGTGTAGGGCTGTGGTGGGTCTA, Reverse: 
GAGAGGCAGTTCAAGCCAAG. The forward primers contained an M13 (-20) forward 
sequencing primer for subsequent Sanger sequencing analysis for the presence of wild-
type and mutant alleles. 
Expression of mutant IDH1/2 was verified via cDNA sequencing on two clones 
for each gene. RNA was extracted using the RNeasy Kit (Qiagen, CA, USA) per 
manufacturer’s protocols. iScript cDNA Synthesis Kit (BioRad, CA, USA) was used to 
 PGK-­‐neo STOP E2/ E3/4 
R132H/R172
K 
E2 E3 E4     Wild-­‐Type	  Locus 
Targeting	  Vector 
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generate cDNA for sequencing. KAPA Taq polymerase was used for amplification of the 
region of interest. DNA was amplified using the following primers for IDH1: Forward: 
GTAAAACGACGGCCAGTTCACCAAAGATGCTGCAGAG, Reverse: 
AGGCCCAGGAACAACAAAAT. For IDH2: Forward: 
GTAAAACGACGGCCAGTTGTCAAGTGTGCCACAATCA, Reverse: 
GGGGTGAAGACCAACTTGAA. The forward primers contained an M13 (-20) forward 
sequencing primer for subsequent Sanger sequencing for analysis of the presence of 
both wild-type and mutant alleles. 
Expression was also verified through measurement of 2-HG generation. Cells 
were washed, pelleted, and stored at -80ºC. Cells were then thawed and lysed on ice 
with pre-chilled M-PER Mammalian Protein Extraction Reagent (Thermo Scientific) with 
complete protease inhibitor cocktail (Roche) for 15 minutes, then spun down at 4ºC for 
10 minutes at 13,200 rpm. Protein concentration was measured in an aliquot of each 
sample using Protein Assay Buffer (BioRad). Concentrations were normalized to 5ųg/ųl 
through addition of M-PER to each sample. Samples were measured by LC-negative 
electrospray ionization-MS/MS as described previously.145,146 
 
4.2.2. Mouse ES Cell Growth 
 
Mouse ES cells were grown on standard cell-culture plates treated with 0.1% 
gelatin solution for 30 minutes prior to use. Cells were placed in these plates in ES 
Media (15% FBS, 50U/mL Penicillin/Streptomycin, 2mM L-glutamine, 0.1mM non-
essential amino acids, 500U/mL leukocyte inhibitory factor, 0.1mM β-mercaptoethanol, 
1mM sodium pyruvate, in GMEM, sterile-filtered) and grown at 37ºC, 6% CO2. Media 
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was replaced with fresh media every 24 hours. Cells were passaged every 2-3 days 
when plates reached approximately 80% confluence. Fresh ES Media was exchanged 
for old media on plates 3 hours prior to passaging. For passaging, cells were washed 
with Phosphate-Buffered Saline (PBS) without bivalent cations (Gibco). 0.25% 
trypsin/EDTA was added, and immediately upon dissociation of colonies, medium was 
gently pipetted to dissociate colonies into single cells. Following dissociation, washing 
media (ES Media without leukocyte inhibitory factor) was added to inactivate trypsin, and 
cells were spun down at 1,000 rpm for 4 minutes. After removing the supernatant, cells 
were resuspended in fresh ES Media (usually at a 1:5 or 1:6 dilution), and plated on 
gelatin-treated cell culture dishes. Plates were gently rocked to achieve a uniform 
distribution. 
	  
4.2.3. Measurement of 2-HG in Mouse ES Cells 
 
2-HG was measured in mouse ES cells with and without mutant IDH1/2. ES cells 
were plated as described in Section 4.2.2 in 60mm cell culture dishes. Following 2 days 
of growth, cells were removed with trypsin and washed as described in Section 4.2.2. 
Following the second wash with PBS, cells were spun down at 1,000 rpm for 4 minutes, 
supernatant was removed, and the pellet was stored at -80ºC. Pellets were thawed on 
ice and resuspended in cold M-PER. Cells were lysed on ice for 15 minutes, then spun 
down at 4ºC for 10 minutes at 13,200 rpm. Supernatant was saved, and protein 
concentration was measured using Protein Assay Buffer (BioRad) and compared to a 
Pre-diluted Protein Assay Standards BSA Set (Thermo). Protein concentration in 
samples was normalized using additional lysis buffer, with concentration normalized to 
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12µg/µL. Samples were measured by LC-negative electrospray ionization-MS/MS as 
described previously.145,146 
 
4.2.4. Metabolic Profiling of Mouse ES Cells Expressing Mutant 
IDH1/2 
 
To assess the changes occurring in mouse ES cells with mutant IDH1/2, we, in 
collaboration with Metabolon, completed metabolic profiling using three mass 
spectrometry platforms: liquid chromatography (LC)-MS/MS with electrospray ionization, 
(LC)-MS/MS without electrospray ionization and gas chromatography (GC)-MS to 
assess metabolic profiles as previously described.147-150 Mouse ES cells were grown at 
37ºC 6% CO2 in 60mm plates as described in Section 4.2.2. Two plates were combined 
for each measured sample. Five biological replicates were generated for each cell line 
studied (ten plates total per line, as two 60mm cell culture plates were combined to 
collect 107 cells, as required for sampling). Cells lines utilized were: E14 parental, IDH1 
Clone B9, IDH1 Clone C6, IDH2 Clone B8, and IDH2 Clone C5. Each plate was placed 
in a different location within the incubator so as to minimize variability in results from 
slight differences in temperature or humidity. Cells were washed with pre-warmed PBS. 
0.25% pre-warmed trypsin was added to each plate, and plates were rotated gently to 
encourage cells to enter suspension. Following suspension of cells, washing media (ES 
cell media without growth factors) was added to each sample to inhibit trypsin, and 
plates were again gently rocked. Cells were spun down for 4 minutes at 1,000 rpm and 
resuspended in fresh PBS. Cells were counted using trypan blue and a 
haemocytometer. Values from three counts per sample were averaged to determine the 
concentration of cells. 107 cells were collected for each sample and spun down for 4 
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minutes at 1,000 rpm. PBS was removed, and cells were flash frozen on dry ice and 
stored at -80ºC until transfer to Metabolon. 
 
4.2.5. Assessment of Oxidative Stress 
 
We assessed the impact of mutant IDH1/2 on response to oxidative stress 
utilizing Hct116 cell lines. These lines were generated using homologous recombination 
to allow for expression of mutant IDH1. These lines were generated in the lab by Chris 
Duncan as described previously.151 Studies were completed with parental Hct116 or 
Hct116 IDH1R132H clone 1D3. Oxidative stress was measured using -5-(and-6)-carboxy-
2’,7’-dichlorodihydrofluoroscein diacetate (H2DCFDA) (Invitrogen). For visualization 
studies using a microscope, cells were grown in 24-well plates at 50,00 cells per well for 
48 hours prior to the study. For FACS studies, cells were grown in 6-well plates at a 
concentration of 200,000 cells per well for 24 hours at 37ºC, 5% CO2. For pseudo-
hypoxia to generate oxidative stress, cells were treated with 200µM CoCl2 for 18 hours. 
All procedures involving H2DCFDA were completed in low light levels.  
For direct microscopic visualization, wells were washed with DPBS and placed in 
fresh media. H2DCFDA was then added to the media for a final concentration of 1µM, 
and plates were incubated at 37ºC, 5% CO2 for 8 minutes. As a positive control, cells 
were stressed with 50µM H2O2 for 15 minutes for visualization studies using a 
microscope. Cells were visualized every 15-30 minutes with excitation at 465-495nm. 
 For FACS, one population of wells was treated with 5µM H2O2 for 10 minutes as 
a stressor. All wells were washed with PBS and treated with trypsin. Cells were 
resuspended in McCoy’s medium, which inactivated the trypsin. Cells were spun for 3 
minutes at 1,260 rpm. Cells were washed twice in fresh 1% bovine serum albumin (BSA) 
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in PBS, and spun between washes as previously described. 50ųg of H2DCFDA was 
dissolved in 17.3ųL DMSO and, and 12.8µl was added to 16mL 1% BSA/PBS to yield a 
final carboxy-H2DCFDA concentration of 1ųM, or 580ng/ųL. Cells from each well were 
resuspended in 2.5mL 1µM H2DCFDA solution, placed in a fresh 6-well plate, and 
incubated at 37ºC, 5% CO2 for 15 minutes. Cells were spun down for 3 minutes and 
resuspended in 2mL of 1% BSA in PBS, and analyzed by flow cytometry using a 
FACSCalibur flow cytometer (BD Biosciences, USA) using the FITC channel (approx. 
492nm excitation/520nm emission). Cells were gated such that approximately 3-5% of 
parental cells were positive at baseline. 
These same studies were also completed with our mouse ES cell lines. For 
mouse ES cells, studies were completed with parental, one mutant IDH1 clone, and one 
mutant IDH2 clone. Oxidative stress was measured using H2DCFDA (Invitrogen). Cells 
were grown in 6-well plates at a concentration of 90,000 cells per well.  
For pseudo-hypoxia to generate oxidative stress, cells were treated with 200µM 
CoCl2 for 18 hours. All procedures involving H2DCFDA were completed in low light 
levels. As a positive control, cells were stressed with 2.5µM H2O2 for 10 minutes. For 
direct microscopic visualization, wells were then immediately visualized with excitation at 
465-495nm. 
For FACS sorting, wells were washed with PBS. Wells were treated with trypsin, 
and cells resuspended in DMEM, which inactivated the trypsin. Cells were spun for 3 
minutes at 1,260 rpm. Cells were washed twice in fresh 1% BSA in PBS, and spun 
between washes as previously described. 50ųg of H2DCFDA was dissolved in 17.3ųL 
DMSO and, and 12.8µl was added to 16mL 1% BSA/PBS to yield a final H2DCFDA 
concentration of 1ųM, or 580ng/ųL. Cells from each well were resuspended in 2.5mL 
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1µM H2DCFDA solution, placed in a fresh 6-well plate, and incubated at 37ºC, 5% CO2 
for 15 minutes. Cells were spun down for 3 minutes, resuspended in 2mL of 
1%BSA/PBS, and analyzed by flow cytometry using the FITC channel. 
 
4.2.6. Analysis of Hypoxia Signaling in Hct116 Cells with Mutant 
IDH1/2 
 
To evaluate the impact of mutant IDH1 on response to hypoxia, we and 
collaborators in the Kaelin laboratory compared HIF-1α protein levels in lines under 
normoxia and mild hypoxia by Western blot.  Hct116 cell lines with or without mutant 
IDH1 or mutant IDH2 were grown for 48 hours at 37ºC, 5% CO2, until they reached 50%-
60% confluence. The appropriate plates were transferred to mild hypoxia of 7.5% O2 for 
16 hours, or normoxia with desferrioxamine (DFO) for 16 hours, while the remaining 
plates stayed in normoxia. Following exposure to mild hypoxia, cell culture dishes were 
placed on ice, and washed with cold PBS. Cells were dissociated with a cell scraper, 
gently suspended in PBS, and spun down at 4ºC, 1,000 rpm for 4 minutes. Cells were 
resuspended in lysis buffer (50mM Tris pH 7.5 150mM sodium chloride, 0.5% Nonidet P-
40, complete protease inhibitor cocktail tablet [Roche], 5mM sodium fluoride, 1mM 
sodium pyrophosphate, 1mM β-glycerophosphate, 1mM dithiothreitol), allowed to sit for 
15 minutes on ice, the spun down at 4ºC for 10 minutes at 13,200 rpm. Supernatant was 
saved, and protein concentration was measured using Protein Assay Buffer (BioRad) 
and compared to a Pre-diluted Protein Assay Standards BSA Set (Thermo). Protein 
concentration in samples was normalized using additional lysis buffer. Loading buffer 
(Laemmli Sample Buffer [BioRad] with β-mercaptoethanol) was added to samples, and 
was placed at 90ºC for 3 minutes. Samples were loaded onto NuPage 4-12% Bis-Tris 
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Gel (Invitrogen) and run at 150 volts for approximately 1 hour. Protein was transferred 
onto PVDF using semi-dry transfer, and blocked for one hour in washing buffer (10mM 
Tris, pH 7.5, 150mM sodium chloride, 0.05% TWEEN-20) with 5% powdered milk  
(weight/volume). Membrane was transferred to washing buffer with 5% BSA and anti-
HIF-1α antibody (BD-Biosciences 610958) or blocking buffer and anti-PHD2 antibody 
(Cell Signaling D31E11). Membrane was placed at 4ºC overnight. Following exposure to 
primary antibody, membrane was washed in washing buffer with 5% powdered milk 
(weight/volume) 3x 10minutes with shaking at room temperature. The membrane was 
then placed in blocking buffer with secondary anti-mouse HRP-conjugated antibody 
diluted 1:10,000 (GE Healthcare NA9231V). This was placed at room temperature with 
shaking for 45 minutes, then washed 3x 15 minutes with shaking at room temperature in 
washing buffer. Detection was completed using Super Signal West Femto Maximum 
Sensitivity Substrate (Thermo), and detected using autoradiography film. The same 
procedure was completed with anti-GAPDH or anti-tubulin antibody as a control. 
 
4.2.7. Measurement of 5-hydroxymethylcytosine in Mouse ES Cells 
Expressing Mutant IDH1/2 
 
We, in collaboration with Dr. Lucy Godley at the University of Chicago, measured 
5-hydroxymethylcytosine (5hMC) levels in the IDH1/2 mutant mouse ES cell lines as well 
as the parental line using a dot-blot assay to assess global levels of 5-
hydroxymethylcytosine.152 Briefly, labeled (for identification of 5-hydroxymethylcytosine) 
genomic DNA was blotted onto a membrane, blocked with BSA, and treated with avidin-
HRP for measurement of chemiluminescence.152 For further quantification, we and 
collaborators utilized LC/MS to assess changes in global levels between mutant and 
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E14  represents  the  parental,  wild-­‐‑type  line.  
Sequences:  (at  codon  132)  wild-­‐‑type  IDH1:CGA,  mutant  IDH1:CAC;  (at  codon  172)  
wild-­‐‑type  IDH2:AGG,  mutant  IDH2:AAG.  
  
wild-type cell lines. These studies allow us to see if there are large global changes in 
levels of 5-hydroxymethylcytosine. 
 
4.3. Results 
 
4.3.1. Verification of Mouse ES Cell Generation 
 
Heterozygosity of mouse ES cells for mutant IDH1 or mutant IDH2 was verified 
by genomic sequencing (Figure 7). Subsequently, mRNA expression from both alleles 
was verified (Figure 8) We also verified 2-HG generation in mutant IDH1/2 lines (Figure 
9). 
 
Figure  7:  Heterozygous  alleles  for  mutant  IDH1  or  mutant  IDH2  in  mouse  ES  cell  
clones  as  determined  by  gDNA  sequencing.  
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E14  represents  the  parental,  wild-­‐‑
type  line.  Sequences:  (at  codon  132)  wild-­‐‑type  IDH1:CGA,  mutant  IDH1:CAC;  (at  codon  172)  
wild-­‐‑type  IDH2:AGG,  mutant  IDH2:AAG.  
  
E14  
represents  the  parental,  wild-­‐‑type  line.  
  
 
Figure  8:  Heterozygous  expression  of  mutant  and  wild-­‐‑type  IDH1  or  IDH2  in  
mouse  ES  cells  as  determined  by  mRNA  analysis.  
 
 
 
 
 
Figure  9:  2-­‐‑HG  generation  in  mouse  ES  cells  with  mutant  IDH1/2.  
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4.3.2. Metabolomic Profiling 
 
Metabolic profiling was completed to assess changes in levels of various 
metabolites in mouse ES cells in the setting of mutant IDH1 or mutant IDH2. These 
studies verified generation of 2-HG, with IDH1 mutants showing a 100-fold increase in 
levels and IDH2 mutants showing a 30-fold increase in levels compared to the parental 
line (Figure 10). 
 
  
Figure  10:  2-­‐‑HG  generation  in  mouse  ES  cells  with  mutant  IDH1/2.  
 
  
 
 
Results from metabolic profiling identified an increase in oxidized glutathione in 
mouse ES cell lines with mutant IDH1/2 compared to control (Figure 11). 
Correspondingly, there was an increased ratio of oxidized to reduced glutathione in 
mouse ES cell lines with mutant IDH1/2 compared to control (data not shown). We also 
                                                                       Each  value  
represents  measurements  from  five  biological  replicates.  Error  bars  represent  standard  
deviation.  P<0.0005  for  each  mutant  compared  to  control.  
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identified increased levels of 2-aminobutyrate and ophthalmate in these lines (Figure 
12). Because of the findings of increased oxidized glutathione and increased 
ophthalmate, we assessed responses to oxidative stress in the setting of mutant IDH1/2. 
 
 
Figure  11:  Levels  of  oxidized  glutathione  are  increased  in  mouse  ES  cells  with  
mutant  IDH1/2.  
 
 
                                         
                                           Each  value  represents  measurements  from  five  biological  replicates.  
Error  bars  represent  standard  deviation.  Difference  from  control  was  P<0.05  for  IDH1  C6,  
IDH2  B8,  and  IDH2  C5.  
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Figure  12:  Ophthalmate  levels  are  increased  in  mouse  ES  cells  with  mutant  
IDH1/2.  
 
 
 
4.3.3. Effect of Mutant IDH1/2 on Response to Oxidative Stress 
 
No gross changes or differences were noted visually either at baseline or in 
response to pseudo-hypoxia in Hct116 cells with mutant IDH1 compared to the parental 
line when treated with H2DCFDA to detect reactive oxygen species (Figure 13). 
Likewise, no changes in response were noted in mouse ES cells with mutant IDH1 or 
mutant 2 (Figure 14). 
 
                                       
                            Each  value  represents  measurements  from  five  biological  replicates.  Error  bars  
represent  standard  deviation.  Difference  from  control  was  P<0.2  for  each  mutant  line  
compared  to  control,  but  did  not  reach  statistical  significance.  
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Figure  13:  Mutant  IDH1  and  response  to  oxidative  stress  in  Hct116.  
CoCl2%
WT%
IDH1%
Baseline% Posi3ve%Control%
                                                         Oxidative  
stress  measured  via  fluorescence  in  the  presence  of  H2DCFDA.  Cells  were  treated  with  
CoCl2  for  18  hours  to  mimic  hypoxia.  H2O2  exposure  was  used  as  a  positive  control.  
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Figure  14:  Mutant  IDH1/2  and  response  to  oxidative  stress  in  mouse  ES  cells.  
  
 
We subsequently used a more quantitative approach to measure oxidative 
stress. Utilizing H2DCFDA as a marker of oxidative stress, we measured baseline levels 
and levels following treatment with H2O2 using FACS. However, we did not detect 
significant changes in cell lines with mutant IDH1/2 as compared to the parental lines 
(Figure 15, Figure 16)  
CoCl2%Baseline% Posi-ve%Control%
WT%
IDH1%
IDH2%
Oxidative  stress  measured  via  fluorescence  in  the  presence  of  H2DCFDA.  Cells  were  
treated  with  CoCl2  for  18  hours  to  mimic  hypoxia.  H2O2  exposure  was  used  as  a  
positive  control.  
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    Cutoff  for  positivity  set  to  include  95%  of  
parental  cells  at  baseline.  Error  bars  represent  standard  deviation  of  experiment  
completed  in  duplicate.  P>0.05  for  experimental  lines  compared  to  parental  line  
under  the  same  condition.  
 
Figure  15:  Response  of  Hct116  cells  with  mutant  IDH1  (Clones  1D3  and  2D6)  to  
oxidative  stress  as  measured  by  FACS.  
 
 
 
Figure  16:  Response  of  mouse  ES  cells  with  mutant  IDH1/2  to  oxidative  stress  as  
measured  by  FACS.  
 
  
         Cutoff  for  positivity  set  to  include  95%  of  parental  cells  at  baseline  .    
    Error  bars  represent  standard  deviation.  P>0.05  for  experimental  lines  compared  to    
    parental  line  under  the  same  conditions.  
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4.3.4. Role of Mutant IDH1/2 in Hypoxia Signaling 
 
To assess the response to hypoxia, we exposed Hct116 cell lines with either 
wild-type or mutant IDH1 to mild hypoxia for 24 hours. While levels of HIF-1α increase in 
the setting of hypoxia, the increase in protein is attenuated in mutant IDH1 cell lines 
compared to the wild-type parental cell line (Figure 17).2 These studies were completed 
initially at Duke and replicated in the Kaelin lab with similar results. 
 
Figure  17:  IDH1R132H  attenuates  response  to  hypoxia  in  Hct116.  
 
 
4.3.5. 5-hydroxymethylcytosine Status in Mouse ES Cells with Mutant 
IDH1/2 
 
To assess levels of 5-hydroxymethylcytosine in mouse ES cells, we first 
completed a dot-blot assay, in which the levels in experimental lines are measured as a 
                                       2  N=  normoxia,  H=  
7.5%  oxygen,,  D=  DFO.  Exposure  to  hypoxia  or  DFA  was  for  16  hours.  
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    Y  axis  =  fold  difference  from  levels  in  the  parental  E14  mouse  ES  cell  line.  Error  
bars  represent  standard  deviation.    Values  represent  average  of  two  separate  experiments  
completed  on  different  days.    
  
fraction of levels in the parental line. Compared to the parental line, levels of 5-
hydroxymethylctyosine are decreased in cell lines containing mutant IDH1/2 (Figure 18).  
 
Figure  18:  Global  5-­‐‑hydroxymethylcytosine  levels  in  mouse  ES  cells  with  mutant  
IDH1/2.
 
  
  
  
Following these initial studies, we quantitatively measured levels of 5-
hydroxymethylcytosine. Levels of 5-hydroxymethylcytosine were measured as a fraction 
of total cytosines, and were decreased in cell lines with mutant IDH1 or mutant IDH2 
compared to the parental line, although the decrease in 5-hmC did not reach statistical 
significance.  
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Figure  19:  5-­‐‑hydroxymethylated  cytosines  as  a  percentage  of  total  cytosines.  
 
4.4. Discussion 
 
Mouse ES cells were successfully generated which had successful homologous 
recombination leading to the presence of either mutant IDH1R132H or IDH2R172K, as 
verified by genomic DNA sequencing of the appropriate region (Figure 7). Expression 
was verified through sequencing of mRNA expression from both wild-type and mutant 
alleles (Figure 8), and functional protein was verified through assessment of increases in 
levels of 2-HG (Figure 9).  
 
  Error  bars  
represent  standard  deviation  of  two  biological  replicates.  
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4.4.1. Metabolic Profiling in Mouse ES Cells 
 
We completed metabolic profiling in mouse ES cells in an attempt to understand 
the metabolic changes that occur in a cell with mutant IDH1/2. Over 200 chemicals were 
identified and analyzed in the study. In general, TCA cycle intermediates demonstrated 
only subtle differences in levels. This is in line with findings from metabolic profiles using 
other cell lines within the lab (data not shown). Glutamine was found to be decreased in 
mouse ES lines with mutant IDH1/2 (Figure B- 2). Glutamine has shown to be a source 
of substrate for eventual generation of 2-HG.85 Therefore, if the cells are actively 
generating 2-HG, it is probable that these cells might be depleting glutamine in the 
process. In our own preliminary studies, increased glutamine in the media appeared to 
lead to increased levels of 2-HG (data not shown). However, in a larger sense, there 
were no large trends or changes detected in the levels of TCA cycle intermediates. A 
limitation of these studies is that they represent only one time point. It is possible that 
analyses of flux through the TCA cycle may reveal changes not obvious when looking at 
a metabolic snapshot. Futures studies analyzing flux through pathways, such as studies 
utilizing carbon-labeled substrates, may identify changes not identified through metabolic 
profiling alone. 
However, there were some differences in metabolites that appeared to point to 
potential changes in other pathways. Of note, increases in oxidized glutathione, 2-
aminobutyrate, and ophthalmate were identified (Figure 11, Figure 12, Figure B- 3), 
suggesting an increase in oxidative stress, as will be discussed in the subsequent 
section. 
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4.4.2. Mutant IDH1/2 and Oxidative Stress 
 
The ramifications of mutant IDH1/2 on cellular behavior are still largely unknown. 
IDH1 and IDH2 produce NADPH, a reducing equivalent which confers cellular protection 
against oxidative damage. As GBM patients with IDH1/2 mutations have a longer 
survival than GBM patients with wild-type IDH1/2, we postulated that IDH1/2 mutants 
may provide tumor cells with sensitivity to oxidative stress, such as that conferred by 
chemotherapy or radiation therapy. Metabolic profiling identified an increase in oxidized 
glutathione and an increased ratio of oxidized glutathione to reduced glutathione in 
mouse ES cells with IDH1R132H or IDH2R172K compared to the parental lines (Figure 11). 
Additionally, there was an increase in ophthalmate (Figure 12), and 2-aminobutyrate 
(Figure B- 3), an intermediate in the synthesis of ophthalmate. Ophthalmate has been 
suggested to be a biomarker of oxidative stress.153-155 These two intriguing results 
suggested a degree of increased oxidative stress within the cells even at baseline, since 
they implied the potential for increased flux through the glutathione biosynthesis 
pathway. To assess for baseline level of oxidative stress in cell lines with mutant IDH1/2, 
and the ability to respond to stressors, we measured stress in mouse ES cells and 
Hct116 cell lines with mutant IDH1/2, utilizing H2DCFDA. 
Initial studies using H2DCFDA utilized light microscopy to assess for gross 
changes in fluorescence. These studies were completed in both mouse ES cell lines and 
Hct116 cell lines with mutant IDH1/2, comparing them to the respective parental lines 
either at baseline or under the setting of pseudo-hypoxia. Results were disappointing, as 
there were no clear gross differences in the presence of mutant IDH1/2 (Figure 
13,Figure 14). Therefore, we proceeded to do a more quantitative assessment utilizing 
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FACS. Following exposure to H2DCFDA, cell fluorescence was analyzed using flow 
cytometry, allowing for quantitative measurement of changes in reactive oxygen species 
levels both at baseline and in response to stress. This would allow us to assess if the 
cells were 1) more stressed at baseline or 2) able to compensate at baseline, but more 
sensitive to additional stressors. Again, despite multiple studies utilizing different cell 
lines with mutant IDH1/2, there were no significant differences in fluorescence between 
cell lines with mutant IDH1/2 and those without (Figure 15,Figure 16). This would 
suggest that if there is a difference in levels of oxidative stress, any differences are likely 
too small to be biologically relevant. Studies completed by collaborators in human 
astrocytes with mutant IDH1 utilizing H2DCFDA also did not find significant differences in 
reactive oxygen species either at baseline or under the setting of increased oxidative 
stress.2  
Results of studies by other groups on the implications of 2-HG or mutant IDH for 
cellular stress have yielded conflicting results. Sasaki et al. generated mice which 
expressed mutant IDH1 in a population of brain cells. They found decreased levels of 
reduced glutathione intracellularly in these mice,121 consistent with our findings of 
increased oxidized glutathione in our mouse ES cells expressing mutant IDH1 or mutant 
IDH2. Again, this would appear to suggest increased levels of oxidative stress. However, 
in their in vivo system, they found a decrease in reactive oxygen species as measured 
by H2DCFDA in various populations of brain cells in Nestin-Cre/IDH1R132H mice.121 On 
the other hand, in studies completed by another group, when 2-HG was added to the 
cerebral cortex of rats, there was an increase in oxidative stress.156 Complicating things 
further, studies with mutant IDH1 in myeloid progenitors did not detect a significant 
change in ROS.88 Further research is needed to better understand these paradoxical 
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findings and the specific contexts under which oxidative stress may be increased or 
decreased. 
 
4.4.3. Hypoxia Signaling Impacted by Mutant IDH1 
 
2-HG bears structural similarity to α-ketoglutarate, and studies have found 
inhibition of a number of α-ketoglutarate-dependent dioxygenases in the presence of 2-
HG.87,106,157 Prolyl hydroxylases (PHD), which are α-ketoglutarate-dependent 
dioxygenases, normally function to lead to the ubiquitination and degradation of HIF-1α.  
Because of findings by other labs of inhibition of a number of α-ketoglutarate-dependent 
dioxygenases by 2-HG, we hypothesized that introduction of mutant IDH1 into cell lines 
would lead to an increase in HIF-1α as a response to inhibition of PHDs. Quite to our 
surprise, we found that the presence of mutant IDH1 leads to an attenuated response to 
hypoxia in Hct116 with mutant IDH1 (Figure 17).2 Work in our lab and with collaborators 
found that response to hypoxia as measured by HIF-1α was attenuated in a number of 
different cell lines with mutant IDH1, including human astrocytes and a human 
oligodendroglioma line.2 Further studies with collaborators revealed that, although 2-HG 
is an antagonist of TET2, 2-HG appears to serve as an agonist of PHD2, being 
converted to α-ketoglutarate and serving as a substrate for generation of succinate and 
increased activity of PHD2.2 Gene expression signatures from IDH-mutated 
astrocytomas appear to agree with these findings, suggesting an impaired HIF response 
compared to wild-type astrocytomas of similar grade.2 Thus, whether 2-HG serves as an 
agonist or antagonist of an enzyme is likely dependent on the structure and active site of 
that particular enzyme. 
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Upregulation of hypoxia signaling is often described in cancers as pro-
tumorigenic, as it can lead to increased angiogenesis and assist with growth of the 
tumors. Thus, we were initially surprised to identify a decrease in HIF-1α in our cell lines 
with mutant IDH1, and continued to be surprised as work with further cell lines only re-
affirmed our initial findings.2 However, there are scenarios in which a decrease in HIF-1α 
could be pro-tumorigenic. In one study, a group generated an astrocytoma line in which 
HIF-1α was knocked out.158 This line grew more slowly than the same line with intact 
HIF-1α  when injected subcutaneously in mice, but grew more quickly and more 
invasively when injected in the brain.158 Thus, the surrounding parenchyma may impact 
whether the same mutations are pro-tumorigenic or not. This has serious implications for 
studies attempting to address the implications of hypoxia signaling in gliomas, as context 
is critical. Progressive gliomas are by their nature invasive tumors. The findings from this 
group suggest that changes in HIF-1α may be one factor that modulates that 
invasiveness.  
Hypoxia signaling often leads to increased VEGF and angiogenesis. Yet, low 
grade gliomas are in part defined by a lack of endothelial hyperplasia and a lack of 
microvascular proliferation, features which are observed in and define GBMs.7 An 
attenuation of hypoxia signaling in progressive gliomas by mutant IDH1/2 may be a 
reason why these features are only observed in higher grade tumors. Further research is 
needed to better understand the implications of the presence of mutant IDH1/2 for 
hypoxia signaling in the context of progressive gliomas. Research on other pathways 
have often revealed that different parts of a single pathway may react differently to 
different stimuli; it is not always simply “on” or “off.” Further research utilizing patient 
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samples and mouse models may help further elucidate some of these contradictory 
findings. 
 
4.4.4. 5-hydroxymethylcytosine and Mouse ES Cells 
 
Levels of 5-hydroxymethylcytosine have been shown to decrease in the absence 
of TET2.117,159 2-HG appears to inhibit TET2 function in acute myeloid leukemias, and 
may impair differentiation of hematopoietic precursors.87 Recently, 5-
hydroxymethylcytosine levels were found to increase in the brain throughout 
development into adulthood; the lowest levels of 5-hydroxymethylcytosine were 
identified in neural precursor-like cells and the developing brain.160  
In mouse ES cells, levels of 5-hydroxymethylcytosine change during 
differentiation.115,116 Thus it would be reasonable to assume that mutant IDH1/2 would 
have the potential to impact levels of 5-hydroxymethylcytosine in mouse ES cells. 
Indeed, we found a decrease in the levels of 5-hydroxymethylcytosine in mouse ES cells 
utilizing two different methods to detect 5-hydroxymethylcytosine (Figure 18,Figure 19). 
This is in concordance with what has been found in other cell lines within our lab, and in 
leukemias in other labs.87 We did not detect significant changes in the levels of 5-
methylcytosine (Figure B- 4). This trend appears to hold true in vivo. Recent studies by 
other groups utilizing Nestin-Cre/IDH1R132H/wt mice identified lower levels of 5-
hydroxymethylcytosine in neural stem cells from these mice.121 Studies are underway in 
our lab utilizing cell lines with mutant IDH1 to better understand these epigenetic 
changes.151 
Mutant IDH1/2 appear to impair hematopoietic differentiation in mice, and this 
appears to be correlated with a decrease in 5-hydroxymethylcytosine.87 These studies 
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have the potential to yield insights into leukemias with mutant IDH1/2. Similar studies are 
needed to better understand progressive gliomas. Isolation of neural stem cells in which 
mutant IDH1/2 could be induced would be of particular interest in exploring the 
ramifications of changes in methylation and differentiation. Methylation profiling and 
gene expression studies completed on these cell lines with and without mutant IDH1/2 
both at baseline and after differentiation could provide new insights into which genes are 
turned on or turned off in the presence of mutant IDH1/2.  
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5. Mouse Models of Mutant IDH2 
 
5.1. Introduction 
 
While we and others have completed cell line studies and patient sample studies 
to explore mutant IDH1/2, there are limitations to these studies. A mouse model system 
allows for mutant IDH1/2 cells to interact with the surrounding brain parenchyma and 
immune system. Long-term, mice with mutant IDH2 would allow for assessment of the 
efficacy of novel therapies to treat these deadly cancers. We explored the ability of 
mutant IDH2 to lead to tumorigenesis when induced in neural stem cells in a mouse 
model system. We utilized a conditional mutant IDH2R172K with expression under the 
control of Cre. Utilizing a broad driver, GFAP+, which leads to expression of Cre 
throughout the brain, we were able to generate mice with mutant IDH2 expressed 
broadly throughout the brain. Using a narrower driver requiring induction, Nestin-CreER, 
we were able to induce mutant IDH2 expression in a much more restricted population of 
cells. We also attempted to see if combining the most common mutations seen in 
progressive gliomas, namely, IDH mutation and p53 deletion, would impact tumor 
formation in mice. 
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5.2. Methods 
 
5.2.1. Generation of Mice with Conditional Expression of Knock-in  
IDH2R172K 
 
All studies completed with mice were approved by the Duke Institutional Animal 
Care and Use Committee. To assess the effects of mutant IDH2 in an in vivo modeling 
system, mouse ES cells with conditional expression of mutant IDH2 were generated as 
described previously. Cells that were not treated with Cre, and who thus still retained 
conditional expression of the mutant enzyme, were injected into blastocysts to allow for 
the development of chimeras. These chimeras were used to generate offspring which 
were genotyped for the presence of heterozygous mutant IDH2 (Figure 6). These mice 
were then crossed with mice expressing Cre recombinase in different populations of 
cells. 
To generate heterozygous mutant knock-in mice in which we can study the 
phenotype in the brain, we crossed two types of mice: (a) animals in which one allele of 
the IDH2 gene has been replaced with a mutant allele preceded by a stop signal flanked 
by recombinase recognition sequences (loxp-stop-loxp-mutant exon 3/4) (Figure 4) and 
(b) one of two sets of animals that express the Cre recombinase. The first set is GFAP-
Cre mice, which express Cre broadly in glial cells, particularly in astrocytes.122 The 
second is Nestin-CreERT2 mice,161 which express an inactive Cre in neural stem cells 
(Nestin-CreER mice graciously donated by Gordon Fishell). Following treatment with 
tamoxifen, the Cre relocates to the nucleus, where it is active. These cells with active 
Cre, and all future cells derived from them, including astrocytes and oligodendrocytes, 
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will express heterozygous mutant IDH2. These mice will be referred to as GFAP-
Cre/IDH2R172K/wt and Nestin-CreER/IDH2R172K/wt mice. 
 
5.2.2. Mice with Multiple Mutations from Progressive Astrocytomas. 
 
The most common combination of mutations in progressive astrocytomas is 
mutant IDH1/2 in combination with mutation/deletion of TP53. Therefore, we also 
crossed Nestin-CreER/IDH2R172K/wt mice with p53fl/fl mice to yield mutant IDH1/2 mice 
also heterozygous or homozygous for loxp-p53-loxp (Figure 20). This will allow for the 
presence of mutant IDH2 and deletion of TP53 within the same cells in the brain. 
 
 
Figure  20:  Schematic  of  Nestin-­‐‑CreER  mice.  
 
Nes$n&CreER+
E18.5+
Tamoxifen+
P4+week+
tamoxifen+
Nes$n&CreER,+IDH2R172K/wt++
Nes$n&CreER,+IDH2R172K/wt+,+
p53fl/wt+
Nes$n&CreER,+IDH2R172K/wt+,+
p53fl/fl+
Nes$n&CreER,+IDH2R172K/wt++
Nes$n&CreER,+IDH2R172K/wt+,+
p53fl/wt+
Nes$n&CreER,+IDH2R172K/wt+,+
p53fl/fl+
The  same  schematic  was  repeated  
with  tamoxifen  treated  mice  without  Nestin-­‐‑CreER  as  a  control.  
  60 
 
5.2.3. Induction of Mutant IDH2 in Populations of Cells. 
 
Induction of expression of mutant IDH1 or mutant IDH2 will occur at two stages 
during development. Because human patients with oligodendrogliomas and progressive 
astrocytomas tend to be younger adults, we induced expression of IDH1R132H or 
IDH2R172K at 4 weeks of age, to approximate tumor onset in adults. This was done via 
administration of 200mg/kg of tamoxifen via oral gavage. Induction at 4 weeks of age 
also minimizes the number of non-tumor cells which will express the mutant protein, 
minimizing the chance of phenotypes resulting from expression of mutant IDH1/2 in 
normal tissues, which may confound results. However, because only a small fraction of 
cells will express mutant IDH1/2, this had the potential to be insufficient to allow for the 
formation of tumors. In addition, if tumors in humans form from mature astrocytes or 
oligodendrocytes rather than from stem cells, there is the potential to not see a 
phenotype following induction of mutations in adult mouse neural stem cells, since the 
majority of astrocytes and oligodendrocytes have already developed by this point and no 
longer express Nestin. Therefore, we also administered 3mg tamoxifen via oral gavage 
to pregnant female mice at E18.5 (treatments summarized in Figure 20). Studies with 
Nestin-CreER/EGFP have shown labeling of mature astrocytes and oligodendrocytes in 
mice when tamoxifen is administered at this stage of development.162 This will provide 
two advantages. Because of the earlier induction, a larger population of cells will express 
mutant IDH1/2, thus increasing the odds of tumor formation. In addition, because this will 
lead to the presence of the mutation in both neural stem cells as well as mature 
astrocytes and oligodendrocytes derived from them, this increased the likelihood of the 
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mutation being present in the cell of origin for progressive gliomas, since the mutant 
protein will be expressed in a larger population of cells within the brain.  
Experimental genotypes expressing the aforementioned combinations were 
generated in cohorts of approximately 15-20 mice for each experimental genotype and 
at least 4-20 mice for each control genotype. We included a cohort for each induction 
time (embryonic day 18.5 or postnatal week 4) and monitored for one year for the 
development of neurological symptoms or any signs of distress. Neurological 
dysfunction was checked at least every other day by assessing mice for difficulty with 
ambulation or posture, changes in hair coat, such as lack of grooming, and changes in 
activity level, such as pacing or reluctance to move. Mice that did not develop symptoms 
were sacrificed at 1 year of age to assess for presence of tumors or other abnormalities. 
Mice with symptoms were sacrificed either via intracardiac perfusion or CO2 euthanasia. 
For intracardiac perfusion, mice were injected via intraperitoneal injection with a lethal 
dose of urethane, followed by intracardiac perfusion of at least 15mL of Dulbecco’s 
Phosphate Buffered Saline and 15mL 4% paraformaldehyde to allow for fixation of 
tissues. Survival was calculated as overall survival rate between different genotypes. 
Statistics were completed using GraphPad Prism 6 (GraphPad), with log-rank tests to 
assess significance. 
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5.2.4. X-gal Staining Verification of Cre Activation Following Induction 
 
For verification of successful Cre activation in the appropriate cells in mouse 
brains following treatment with tamoxifen, Nestin-CreER+/- mice were crossed with Rosa-
(loxp-stop-loxp)-LacZ mice (Rosa-LacZ+/-). In these mice, all cells in which Cre was 
activated, and the progeny of those cells, will stain blue in the presence of X-gal. Mice 
were treated with tamoxifen at either E18.5 or P4 weeks of age as described previously. 
At 7-9 weeks of age, mice were administered a lethal dose of urethane, followed by 
intracardiac perfusion with at least 15mL 0.1M phosphate buffer (PB). Following 
exsanguination, mice were perfused with at least 15mL fixation solution (0.1M PB, 2.5% 
glutaraldehyde. 2% paraformaldehyde). Brains were then dissected and placed in chilled 
post-fixation solution (0.1M PB, 2.5% glutaraldehyde) overnight with gentle rocking.  
Brains were washed in cold 0.1M PB for six washed of 10 minutes each with shaking. 
Using a vibratome, brains were sliced into 100µm slices and placed in chilled 0.1M PB. 
A stock K3 solution (100mM K3Fe(CN)6 in 0.1M PB), stock K4 solution (100mM 
K4Fe(CN)6  in 0.1M PB), and stock 5-bromo-4-chloro-3-indoyl-β-D-galacto-pyranoside 
(X-gal) solution (40mg/mL in dimethylformamide) were prepared, and used to make X-
gal buffer (0.1M PB, 10mM K3Fe(CN)6, 10mM K4Fe(CN)6, 0.48mg/mL X-gal). Sections 
were placed in X-gal buffer overnight with gentle shaking at 37ºC in the dark. The 
reaction was stopped with cold Dulbecco’s phosphate buffered saline with calcium and 
magnesium (DPBS) (Gibco, USA). Slices were washed several times in fresh DPBS, 
placed on positively charged slides and coverslipped using an aqueous mounting fluid.  
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5.2.5. 2-HG Measurement in Mice with Mutant IDH2 
 
Mice that were either GFAP-Cre or GFAP-Cre/IDH2R172K/wt were euthanized via 
standard CO2 euthanasia. Brains were dissected, cut into quarters (left hemisphere, right 
hemisphere, left cerebellum, right cerebellum), and immediately placed in storage at -
80ºC. Samples were measured by LC-negative electrospray ionization-MS/MS as 
described previously.145,146 
 
5.2.6. Histological Assessment of Tissues 
 
Following fixation overnight in formalin, brains were transferred to 70% ethanol 
for paraffin-embedding. To allow for assessment for the presence of brain tumors, brains 
were sliced in horizontal sections. 5µm sections were obtained. A series of 12 sections 
were placed on positively charged slides, followed by 100µm steps, throughout the entire 
brain. The first and last section of each set was stained using haematoxylin and eosin 
(H&E) staining to assess for any histological changes in cellular organization or 
appearance, including increased cellular density, pleomorphic nuclei, and mitotic figures. 
Sections and stains of tumors and representative brains were reviewed by a 
neuropathologist. Stains were completed by the Research Histology Laboratory at Duke 
University. Cellular proliferation was assessed using Ki67 staining. Changes in structure 
and organization were assessed using H&E with Luxol Fast Blue (LFB). Brains with 
mucin-like material were stained with Periodic Acid Schiff (PAS). Brains with 
accumulations of cells of unclear type were stained with anti-GFAP and anti-S-100. 
Immunohistochemical  staining was complete by Zuowei Su at the Duke Research 
Histology Lab. Tumors were additionally stained with anti-cytokeratin, anti-desmin, and 
anti-smooth muscle actin as needed. 
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5.3. Results 
 
5.3.1. GFAP-Cre Mouse Model System 
 
To assess whether functional IDH2 could be activated in cells within the brain, 
we measured levels of 2-HG following activation by Cre. Because GFAP-Cre leads to a 
broader expression of Cre throughout the brain, we assessed for generation of 2-HG in 
symptomatic GFAP-Cre/IDH2R172K/wt mice.  
 
Figure  21:  GFAP-­‐‑Cre/IDH2R172K/wt  mice  generate  2-­‐‑HG.  
  
 
P<0.005.  Error  bar  
represents  standard  deviation  for  four  GFAP-­‐‑Cre  mice  and  three  GFAP-­‐‑
Cre/IDH2R172K/wt  mice.  
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Figure  22:  GFAP-­‐‑Cre  mice  and  brain  histology.  
  
A portion of GFAP-Cre/IDH2R172K/wt mice became symptomatic even prior to 
weaning. Symptoms included ataxia and head doming. The mice also had what could 
either be described as seizures or dystonic posturing. These mice demonstrated a 
several hundred-fold increase in 2-HG compared to GFAP-Cre littermates (Figure 21). 
Upon dissection, brains of GFAP-Cre/IDH2R172K/wt mice appeared to have enlarged 
lateral ventricles, as the brains collapsed inward bilaterally. H&E revealed brains with 
spongiform change throughout the parenchyma (Figure 22, Figure 23). 
 
Figure  23:  GFAP-­‐‑Cre/IDH2R172K/wt  and  spongiform  change.    
  
A" B"
B"A"
                     H&E  with  Luxol  Fast  Blue.  A)  
GFAP-­‐‑Cre/IDH2R172K/wt  mouse,  B)  GFAP-­‐‑Cre  mouse.  
  
                     H&E  with  Luxol  Fast  
Blue.  20x  magnification  vs.  Fig.21.  A)  GFAP-­‐‑Cre/IDH2R172K/wt  mouse,  B)  GFAP-­‐‑Cre  
mouse.  
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5.3.2. Verification of Nestin-CreER Mouse Model System 
 
Nestin-CreER, because it requires tamoxifen for active Cre, and because Cre is 
only present in Nestin+ cells, does not lead to the same level of broad expression of Cre 
as does GFAP-Cre. To assess where cells with mutant enzyme would be present, we 
treated Nestin-CreER/Rosa-LacZ+/- with tamoxifen or corn oil at either E18.5 or P4 
weeks of age. The greatest population of cells stained positive in mice treated at E18.5, 
with a smaller population affected in mice treated at P4 weeks of age. Of note, a small 
population of cells remained positive in untreated mice, suggesting some background 
“leakiness.” The largest population of positive cells were present in the subventricular 
zone through the rostral migratory stream to the olfactory bulb. (Figure 24,Figure 25) 
Another population of cells was identified in the dentate gyrus of the hippocampus 
(Figure 26). Cells within the cerebellum also stained positive (not shown). In all treated 
mice, the brainstem demonstrated a greater degree of sporadically positive cells than 
the cortex (data not shown). 
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Figure  24:  LacZ  generation  is  induced  in  the  subventricular  zone  and  olfactory  
bulb  of  treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mice.    
 
 
 
A"
C" D"
B"
                     Horizontal  view  of  rostral  migratory  
stream  going  into  the  olfactory  bulb  on  the  left.  A)  E18.5-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑
LacZmut/wt  mouse,  B)  P4  week-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  C)  corn  oil-­‐‑
treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  D)  E18.5-­‐‑treated  Rosa-­‐‑LacZ+/-­‐‑  mouse.  
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Figure  25:  LacZ  generation  is  induced  in  the  SVZ  of  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  
mice.    
C" D"
A" B"
Horizontal  view  of  SVZ  ,  demonstrating  increasing  levels  of  positive  following  
treatment  with  tamoxifen.  A)  E18.5-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  B)  P4  
week-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  C)  corn  oil-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑
LacZ+/-­‐‑  mouse,  D)  E18.5-­‐‑treated  Rosa-­‐‑LacZ+/-­‐‑  mouse.  
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Figure  26:  Active  Cre  is  induced  in  the  dentate  gyrus  of  Nestin-­‐‑CreER/Rosa-­‐‑
LacZ+/-­‐‑  mice  following  treatment  with  tamoxifen.  
 
 
 
 
5.3.3. Symptomatic Mice Have Increased 2-HG 
 
To evaluate the changes in 2-HG under varying conditions, we measured 2-HG 
in mice with and without IDH2R172K in varying scenarios. Mice without active IDH2R172K/wt 
demonstrated levels of 2-HG between 0-5µg/mL lysate. An asymptomatic E18.5-treated 
Nestin-CreER/IDH2R172K/wt mouse euthanized at the one-year time point demonstrated a 
>5-fold increase in 2-HG in the cortex compared to controls. Mice with neurological 
symptoms had a >200-fold increase in levels of 2-HG in their cortex compared to 
A" B"
C" D"
                            Horizontal  view  of  hippocampus,  
demonstrating  increasing  levels  of  positive  staining  in  the  dentate  gyrus  (arrow)  
following  treatment  with  tamoxifen.  A)  E18.5-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  
B)  P4  week-­‐‑treated  Nestin-­‐‑CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  C)  corn  oil  treated-­‐‑Nestin-­‐‑
CreER/Rosa-­‐‑LacZ+/-­‐‑  mouse,  D)  E18.5-­‐‑treated  Rosa-­‐‑LacZ+/-­‐‑  mouse.  
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controls. Some E18.5-treated Nestin-CreER/IDH2R172K/wt/p53fl/fl mice developed flank 
tumors, which also demonstrated a >100-fold increase in 2-HG over that measured in 
the cortex of mice without mutant IDH2. 
 
 
Figure  27:  2-­‐‑HG  is  increased  in  symptomatic  mice.                         Compared  to  control  mice  
without  IDH2  mut/wt,  there  is  an  increase  in  2-­‐‑HG  in  treated  mice.  Tissue  analyzed  is  
brain  unless  otherwise  specified  as  a  flank  tumor.  
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5.3.4. Presence of Mutant IDH2 and/or p53 Deletion Impacts Survival 
 
When treated embryonically at E18.5, Nestin-CreER/IDH2R172K/wt/p53fl/fl mice (in 
red) demonstrated a significant difference in overall survival (p<0.005) compared to 
E18.5-treated Nestin-CreER/IDH2R172K/wt mice (in yellow) or Nestin-CreER/p53fl/fl mice (in 
orange) (Figure 28). While some mice treated at P4 weeks developed symptoms 
requiring euthanasia, the fraction of mice to become symptomatic was smaller compared 
to E18.5 (survival curves in Appendix Figure B- 6). 
  
Figure  28:  Presence  of  mutant  IDH2  and/or  p53  deletion  impacts  survival  in  
Nestin-­‐‑CreER  mice  induced  at  E18.5.  
 
None of the E18.5-treated Nestin-CreER/IDH2R172K/wt/p53fl/fl mice or Nestin-
CreER/IDH2R172K/wt/p53fl/wt mice survived to one year, whereas a fraction of the mice in 
all other groups survived to one year (Figure B- 5). 
 
  
  Colors/lines  not  visible  did  not  have  any  deaths    
reported  over  the  one  year  in  which  they  were  monitored.  
(days) 
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5.3.5. Tumors in E18.5-treated Nestin-CreER/IDH2R172K/wt/p53fl/fl Mice 
 
An E18.5-treated Nestin-CreER/IDH2R172K/wt/p53fl/fl developed head doming and 
difficulty with ambulation at 132 days of age. The mouse was euthanized as previously 
described and the brain formalin-fixed and paraffin-embedded. H&E analyses revealed a 
large central mass (Figure 29). 
 
 
Figure  29:    Tumor  in  E18.5-­‐‑treated  Nestin-­‐‑CreER/IDH2R172K/wt/p53fl/fl  mouse.  
 
Histological analyses revealed a migrating edge rather than pushing borders. 
Subarachnoid infiltration and peri-vascular infiltration were also present; additionally, 40-
50% of tumor cells stained positive for Ki67 (Figure 30), a marker of proliferation. 
Immunohistochemical stains of the tumor were negative for staining utilizing anti-S-100, 
anti-GFAP, anti-CD45, and anti-pan-cytokeratin antibodies. S-100 positive reactive 
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astrocytes were present, as were some activated macrophages as identified through 
CD45 staining. 
 
Figure  30:  Staining  reveals  elevated  Ki67  in  brain  tumor  from  E18.5-­‐‑treated  
Nestin-­‐‑CreER/IDH2R172K/wt/p53fl/fl  mouse.  
 
Two E18.5-treated Nestin-CreER/IDH2R172K/wt/p53fl/fl developed tumors on their 
flanks (one was euthanized at 304 days, while the other was euthanized at 154 days). 
Despite a lack of neurological symptoms, the presence of visible growth led to the 
decision to euthanize the mice. Both the tumors and brains from each mouse were 
paraffin-embedded. In one mouse, upon evaluation of the brain, we also identified 
tumor-like cells with an astrocytic appearance, fibrillar processes, and mucin in both 
olfactory bulbs (Figure 31). 25-30% of tumor cells stained positive for Ki67 (Figure 31). 
Tumor cells were focally positive for GFAP, and 20-30% of cells stained positive against 
S-100 (Figure B- 7). 
B"A"
A)  H&E  stain,  B)  Ki67  stain.  
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Figure  31:  Disorganization  and  increased  Ki67  in  the  OB  of  an  E18.5-­‐‑treated  
Nestin-­‐‑Cre/IDH2R172K/wt/p53fl/fl  mouse.  
 
This same mouse was euthanized initially because of a tumor identified in the 
flank. Like the tumor in the olfactory bulb, the flank tumor was also focally S-100 positive 
(Figure B- 7). It had a higher Ki67, with 40-50% of cells staining positive (Figure 32). 
However, GFAP was negative (Figure B- 7). 
! !E18.5'treated! ! ! ! ! ! ! !E18.5'treated!
Nes/n'CreER/IDH2R172K/wt/p53fl/fl ! ! ! ! !IDH2R172K/wt !!
A! B!
C! D!
H&E!
Ki67!
A,B)  H&E  stain,  C,D)  Ki67  stain.  A,C)  Experimental  
mouse.  B,D)  Control  E18.5-­‐‑treated  IDH2R172K/wt  mouse.  
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Figure  32:  Flank  tumor  in  E18.5-­‐‑treated  Nestin-­‐‑CreER/IDH2R172K/wt/p53fl/f  mouse.  
 
The second mouse to develop a flank tumor was also E18.5-treated Nestin-
CreER/IDH2R172K/wt/p53fl/fl. The brain from this mouse appeared to be histologically 
normal. The flank tumor demonstrated pleiomorphic nuclei, carcinoma-like appearance, 
and Ki67 positivity in 25-30% of cells (Figure 33). GFAP and S-100 were negative 
(Figure B- 8) 
 
Figure  33:  Flank  tumor  in  E18.5-­‐‑treated  Nestin-­‐‑CreER/IDH2R172K/wt/p53fl/fl  mouse.  
 
  
A" B"
A" B"
A)  H&E  stain,  B),  Ki67  stain.  
A)  H&E  stain,  B),  Ki67  stain.  
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5.4. Discussion 
 
5.4.1. GFAP-Cre IDH2 Mice Have Severe Developmental Abnormalities 
 
A recent study involving a conditional mutant IDH1R132H explored the phenotypes 
that developed in the setting of mutant IDH1 under different drivers. When driven by 
Nestin-Cre, which leads to very broad expression, these mice developed hemorrhage 
and large cavities within the brain and died within a few days after birth.121 GFAP-
Cre/IDH1R132H/wt mice develop a milder phenotype, with some still exhibiting hemorrhage, 
but others surviving until adulthood.121 Correspondingly, 2-HG levels in the brains of 
mice corresponded with the severity of the phenotype in the mice.121 
We generated mice with GFAP-Cre driven IDH2R172K. A fraction of the GFAP-
Cre/IDH2R172K/wt mice developed severe ataxia and seizures. When 2-HG was measured 
in brains of these symptomatic mice, these mice had significant increases in 2-HG in the 
brains compared to baseline (Figure 21). Grossly, brains from these mice also 
developed large cavities, with hydrocephalus and enlarged lateral ventricles. 
Histologically, these brains exhibited spongiform change and encephalomalacia. 
However, despite these striking changes, there were no signs of tumors in GFAP-
Cre/IDH2R172K/wt mice. It seems likely that the exceedingly high levels of IDH2 
expression, and concomitant increase in 2-HG, led to neurological effects, such as those 
observed in patients with 2-hydroxyglutaric aciduria.163 While no tumors were observed 
in the GFAP-Cre/IDH2R172K/wt mice, these findings do provide a unique opportunity with 
these mice. To our knowledge, there are currently no models of 2-hydroxyglutaric 
aciduria, and only one case report including a post-mortem analysis of histological 
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changes in the brain.126 The changes observed in these mice, including hydrocephalus 
and encephalomalacia, appear to be consistent with what has been reported on MRI in 
humans with this disease.123,125,129 This model could provide a means in which to better 
understand the neurological changes that occur in patients with mutant IDH2-based 2-
hydroxyglutaric aciduria. An obvious alternative model is the generation of a mouse with 
germline expression of mutant IDH2 in all cells as are seen in some of these patients. 
However, in mouse models we generated, this is embryonic lethal (data not shown). To 
study 2-hydroxyglutaric aciduria with a viable model would require inducing the mutation 
later in life in all cells. Although this is certainly an important model and also one worth 
pursuing in the future, if any of the observed changes are a result of 2-HG early in life, 
they would be missed. Thus, GFAP-Cre/IDHR172K/wt mice may provide a means in which 
to better understand the neurological changes, and a system in which to begin to test 
potential treatments to either directly inhibit mutant IDH2 function or indirectly ameliorate 
some of the neurological symptoms. 
 
5.4.2. Treated Nestin-CreER/IDH2R172K/wt Mice 
 
In our continuing attempts to generate a model system for progressive gliomas, 
we then proceeded to generate Nestin-CreER/IDH2R172K mice with and without other 
mutations observed in progressive gliomas. To our knowledge, these are the first mouse 
models generated in which there is expression of mutant IDH2. 
To assess the effectiveness of treatment of our mice with one oral dose of 
tamoxifen at either E18.5 or P4 weeks of age, we utilized Nestin-CreER/Rosa-LacZ+/- 
mice treated at the aforementioned time points (Figure 20). Previous studies by other 
groups utilizing Nestin-CreERT2 reported that treatment of Nestin-CreER/Rosa-LacZ+/- 
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mice leads to activation of Cre and subsequent recombination of cells largely within the 
subventricular zone (SVZ) and also to an extent with in the subgranular zone.164 With 
time, the progeny of these cells become present in the olfactory bulb and the granule cell 
layer of the dentate gyrus.164 Our findings were consistent with these results. 
We treated Nestin-CreER/Rosa-LacZ+/- at either E18.5 or P4 weeks with 
tamoxifen, and sacrificed the mice at 7-9 weeks of age to assess activity using X-gal. 
Populations of positive cells were identified in the SVZ (Figure 25), with an additional 
population in the rostral migratory stream going into the olfactory bulb (Figure 24). 
Verification of expression in the subventricular zone was critical. Studies have identified 
that cells in the subventricular zone are more prone to malignant transformation than 
peripheral astrocytes.165,166 There were additional populations identified in the dentate 
gyrus of the hippocampus (Figure 26). Positive cells were also identified in the 
cerebellum, with positive cells in the Purkinje layer with processes extending out into the 
molecular layer, consistent with Bergmann glia cells (data not shown), which have been 
reported in other models.167 Of note, there was a dose-dependent increase in the 
number of positive cells. In E18.5-treated mice, cells in the corpus callosum were 
positive in addition to the aforementioned regions. In P4-treated mice, although cells 
were positive in all regions, there was a gross decrease in the degree in positivity. Of 
note, there is a degree of background leakiness, as sporadic positive cells were 
identified in the brains of mice treated with only corn oil. Thus, there is a theoretical 
potential for the development of symptoms in untreated mice due to the leakiness of 
Nestin-CreER at baseline. In a small cohort of mice of the experimental genotypes but 
treated with corn oil and monitored over one year, no deaths were observed (data not 
shown). 
  79 
We were able to identify an increase in 2-HG in the brains of treated mice. 
Previous reports suggest that, in mice with mutant IDH1 expressed in the brain, severity 
of symptoms correlates with the levels of 2-HG measured in the brain.121 We identified 
the strongest neurological symptoms in mice with GFAP-Cre/IDH2R172K, which should 
have a broader expression than a system requiring induction for expression. We were 
uncertain if 2-HG levels would be detected in the brains of Nestin-CreER/IDH2R172K/wt 
mice, as only a small fraction of the cells in these brains would be generating 2-HG. In 
mice that developed neurological symptoms, we noted a several hundred-fold increase 
in the levels of 2-HG over that observed in mice without mutant IDH2. However, we 
questioned if this was an increase over the baseline in asymptomatic mice, which we 
had yet to measure. In other words, is 2-HG elevated in all treated Nestin-CreER mice 
with mutant IDH2 at all times, including asymptomatic mice, or does the fraction of 
IDH2R172K-positive cells increase over time in some mice and lead to a corresponding 
increase in 2-HG and onset of symptoms? We measured 2-HG levels in an 
asymptomatic mouse with Nestin-CreER/IDH2R172K/wt that reached one year of age. 
Levels of 2-HG in the asymptomatic Nestin-CreER/IDH2R172K/wt were five-fold higher than 
levels of 2-HG in the brains of mice without IDH2. However, in symptomatic mice, the 
levels of 2-HG were over 100-fold higher. This would suggest that mice that become 
symptomatic either 1) have a larger mutant IDH2-positive population to begin with, 
eventually leading to neurological symptoms or 2) the mutant IDH2-postiive population in 
these mice increases over time, whether as a tumor or as an expansion of a population 
of cells normally present in the brain. As this was done with a small number of mice, 
more studies are needed to verify these observations, strengthen the correlation, and 
evaluate which hypothesis is more probable. 
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The presence of mutations in IDH2 or deletion of p53 appears to impact survival 
in E18.5-treated Nestin-CreER mice. The difference in survival was significant for E18.5-
treated Nestin-CreER/IDH2R172K/wt mice vs. E18.5-treated Nestin-
CreER/IDH2R172Kwt/p53fl/fl at p<0.005 and for E18.5 Nestin-CreER/IDH2R172Kwt mice vs. 
E18.5 Nestin-CreER/IDH2R172Kwt/p53fl/wt at p<0.05.  The difference in survival between 
E18.5 Nestin-CreER/IDH2R172Kwt/p53fl/fl mice and E18.5 Nestin-CreER/IDH2R172Kwt/p53fl/wt 
mice did not reach significance at p<0.2. Thus, the addition of p53 deletion, whether 
heterozygous or homozygous, to IDH2-mutated mice was correlated with a significant 
change in survival compared to mice with only mutant IDH2. Conversely, the addition of 
IDH2 to p53-homozygously deleted mice was also correlated with a significant difference 
in survival compared to mice with only p53 deletion. There was no significant difference 
in survival between those mice that had only mutation of IDH2 or only deletion of p53. It 
is worth noting that not all mice died of neurological causes. One mouse died from a GI 
obstruction, while another died from a renal obstruction, and yet another died from what 
might have been an inflammatory meningitis. For some mice, we were unable to 
determine the cause of death, and therefore could not rule in or rule out a brain tumor as 
a cause. For mice that were found dead, some of the brains were too degraded to 
interpret. Thus, to reflect this uncertainty, all survival curves refer to overall survival only. 
It is unclear if this difference in survival, therefore, is due solely to the presence of brain 
tumors, or if there is a non-CNS tumor pathology that is impacting the survival of the 
mice with both p53 deletion and IDH2 mutation more so than the mice with only one of 
these. Studies with a larger cohort of mice might help elucidate this. 
We identified a tumor in the brain of an E18.5-treated Nestin-
CreER/IDH2R172K/wt/p53fl/fl mice. The central tumor demonstrated an invasive, migrating 
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edge. This tumor had an elevated Ki67, suggesting an aggressive tumor. However, this 
tumor did not stain positive for GFAP or S-100, which are often positive in glial tumors. 
Thus, it remains very possible that this is not a glial tumor, but rather a non-glial tumor 
driven by either mutant IDH2 or p53 deletion. Further stains are needed  to characterize 
this tumor further. 
Interestingly, two E18.5-treated Nestin-CreER/IDH2R172K/wt/p53fl/fl mice developed 
flank tumors requiring euthanasia. One of these mice was also incidentally found to have 
a tumor in the olfactory bulb. However, the other mouse did not have any noticeable 
abnormalities in the brain. The tumor in the olfactory bulb, unlike the centrally-located 
tumor previously discussed, had a more astrocytic appearance, and was focally positive 
for both GFAP and S-100. Because the brain tumor and flank tumor in the one mouse 
shared some features, such as S-100 positivity, but did not share others, such as GFAP 
positivity, it is difficult to conclude one way or the other whether the two tumors are 
related to each other. It is possible that Nestin-CreER has leaky expression in tissues 
outside of the central nervous system. Knockout p53 mice develop other carcinomas 
and sarcomas, but do not develop brain tumors. Thus, we cannot rule out the possibility 
that leaky expression led to the development of a second tumor in the flank of the mouse 
that also had an olfactory bulb tumor. However, noting the presence of abnormalities in 
the olfactory bulb, which have also been identified in others of our mice, at least 
suggests the possibility of a tumor in the brain metastasizing elsewhere. 
It is important to note that to date, no tumors have been identified in the brains of 
Nestin-CreER/IDH2R172K/wt mice without p53 deletion. This would suggest that IDH2 is at 
most a weak oncogenic driver. It is possible that mutations in IDH1/2 provide a cellular 
state in which other mutations are more easily able to promote tumorigenesis. It is 
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interesting to note that p53 knockout mice are not reported to form CNS tumors.66-68 
Likewise, to our knowledge there have been no reports of Nestin-CreER-driven p53 
deletion leading to the development of brain tumors. The presence of two brain tumors 
and two flank tumors in the setting of both IDH2R172K and p53fl/fl is intriguing, but 
insufficient to draw large conclusions; more studies are needed to better understand the 
role of these mutations alone and in conjunction with each other. Studies involving a 
larger cohort of mice may allow us to identify more tumors and identify a trend in the 
types of tumors forming, as well as a more accurate evaluation of the rate of tumor 
formation. Other future studies include the use of different drivers, such as GFAP-
CreER, to drive expression of mutant IDH2 and deletion of p53. The use of a different 
driver to induce these genetic alterations in slightly different cell types may impact the 
rate of tumor formation and the types of tumors formed. This may also provide insight as 
to the cell-of-origin for these tumors. Finally, future studies may include the generation of 
mice with additional mutations frequently observed in human gliomas. These studies 
may help in evaluating the roles of different mutations in gliomas. Additionally, gliomas 
with different mutations may respond differently to treatments. If they can be developed, 
mouse models reflecting the different genetic states of progressive gliomas in patients 
may allow for an improved ability to predict tumor response to various therapies. 
We have identified that the presence of mutant IDH2 and p53 deletion in neural 
stem cells present at E18.5 and all their precursors is sufficient to impact survival in 
mice. We have identified four tumors in three E18.5-treated Nestin-
CreER/IDH2R172K/wt/p53fl/fl mice. Although it is not possible to draw definitely conclusions 
from these studies, they provide a basis upon which to build further studies. Further 
characterization of tumors in this mouse model is critical for evaluation of future utility of 
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the model system. This system holds the potential to provide a true in vivo mouse 
system, not requiring xenografts, in which to study tumors of the brain and mutant IDH2.  
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6. Summary and Future Directions 
 
The identification of mutations in IDH1 and IDH2 in the vast majority of 
progressive gliomas led to a paradigm shift in the study of progressive gliomas. The field 
opened to include previously unidentified pathways as potentially playing a role in the 
development of progressive gliomas. The identification of a marked increase in 2-HG 
generation in the majority of progressive gliomas led to the coinage of the term 
“oncometabolite” to describe a compound that may be responsible for inducing 
tumorigenesis. However, the role that mutant IDH1/2 and 2-HG play in tumorigenesis in 
progressive gliomas is still unclear. Here, we completed a panel of studies involving 
patient samples, metabolic profiling of cell lines, and generation of mouse models to 
evaluate the role of these mutations in gliomas (Figure 34). 
 
 
Figure  34:  Overview  of  studies  exploring  and  characterizing  mutant  IDH.  
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6.1. Assessment of Patient Tumor Samples 
 
Through a series of studies on metastases to the brain, we attempted to ask 
whether these mutations worked to promote tumor growth in brain parenchyma in 
general, or worked to promote growth within a specific cell-of-origin within the brain. We 
did not find any mutations in IDH in tumor metastases to the brain from non-CNS 
tumors. Because mutations in IDH1/2 are among the earliest identified in gliomas, we 
propose that mutations in IDH1/2 may be necessary for tumor initiation when present in 
a specific cell-of-origin. Further studies, utilizing both patient samples and mouse 
models, may help to identify this specific cell-of-origin. Studies with patient samples, 
particularly of low-grade tumors, may identify key features of tumors that share similarity 
with certain cell types within the brain, such as neural stem cells or neural progenitor 
cells. Potential studies include immunohistochemical studies, methylation studies, and 
gene expression studies. Correlation to traits of specific normal cell types within the 
brain would be necessary to begin to be able to draw conclusions regarding a particular 
cell-of-origin.  
 
6.2. Metabolic Profiling 
 
Although the cell-of-origin for progressive gliomas has yet to be identified, we can 
begin to attempt to understand the role mutations in IDH1/2 play in gliomas by utilizing 
other model systems. Mutations in IDH1/2 are present at a high frequency in both 
astrocytomas and oligodendrogliomas, and are among the earliest identified mutations in 
both kinds of tumors. We propose that these mutations may occur in a common 
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precursor cell to both astrocytes and oligodendrocytes. Changes resulting from the 
presence of mutant IDH1/2 that impact a precursor cell may only be observed in vitro in 
studies on a cell line in a more undifferentiated state. Therefore, we utilized mouse ES 
cells with homologous recombination allowing for heterozygous expression of mutant 
IDH1 or mutant IDH2. A summary of our findings and potential implications are 
described in Figure 35. In our studies, we identified a decrease in 5-
hydroxymethylcytosine in these cell lines in the presence of mutant IDH. This is an 
important finding, as levels of 5-hydroxymethylcytosine change in mouse ES cells during 
differentiation.115,116 Additionally, a recent study identified that 5-hydroxymethylcytosine 
is likely to be decreased in human neural stem cells during development, with increased 
levels identified in adult brains.160 Disappointingly, this same study did not identify any 
correlation between IDH1 mutation status and 5-hydroxymethylcytosine levels in the 
tumors evaluated.160 Rather, 5-hydroxymethylcytosine status is associated with tumor 
grade, with the highest grade tumors demonstrating the lowest levels of 5-
hydroxymethylcytosine, although this did not reach statistical significance.160 However, 
this does not necessarily mean that mutations in IDH1/2 do not impact methylation. 
Rather, it suggests that if there are impacts on methylation, they may be more subtle 
than what has been identified with cell lines. Further study is needed to identify genes 
impacted by these mutations. Interesting future directions would involve study of the 
impact of mutant IDH1/2 on neural stem cells and their differentiation, a technically 
challenging, but not impossible endeavor. Novel model systems, such as the use of 
different drivers of mutant IDH1/2, may aid in these studies. The isolation of neural stem 
cells from genetically-engineered mouse models may be a method in which to 
accomplish these studies. Additionally, the utilization of 5-hydroxymethylcytosine or 5-
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methylcytosine pull-down assays and mouse genome profiling on neural stem cells 
following induction of mutant IDH1/2 may allow for identification for genes that may be 
specifically altered as a result of the presence of these mutations. Clearly, more work is 
needed to understand the impacts of mutations in IDH1/2 on methylation and gene 
expression in tumor cells and potential cell-of-origin. 
 
Figure  35:  Potential  changes  results  from  presence  of  mutant  IDH1/2.  
 
6.3. Generation of IDH2 Mouse Models 
Although much information can be gleaned from cell lines and in vitro studies, 
mouse model systems are critical to understanding the role of these mutations in vivo. 
Tumor cells do not exist on their own; they interact with their environment, the immune 
system, and surrounding cells. It is likely that the stem cell niche within the brain may 
play a role in providing a setting in which mutant IDH1/2 may promote tumorigenesis.  
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6.3.1. Mouse Models and 2-hydroxyglutaric aciduria 
 
To study the role of mutant IDH2 in an in vivo system, we generated mice in 
which we could induce heterozygous expression of mutant IDH2R172K in a select 
population of cells within the brain. Broad expression led to severe neurological 
symptoms, including ataxia and seizures. Noting that neurological symptoms are 
frequent in patients with 2-hydroxyglutaric aciduria, this phenotype in our mice likely 
represents toxicity from elevated levels of 2-HG. This opens the opportunity for a unique 
model system in which to better understand the neurological implications of 2-
hydroxyglutaric aciduria, a disease which is neurologically devastating in patients. 
Future studies with this novel model system may involve correlating neurological 
effects with levels of 2-HG generation. Studies in mice with lower levels of 2-HG may 
identify areas that are particularly sensitive to the effects of 2-HG. Symptomatic mice 
with GFAP-Cre/IDH2R172K/wt demonstrated hydrocephalus, encephalomalacia, and 
significant spongiform change. Interestingly, about half of the E18.5-treated Nestin-
CreER/IDH2R172K/wt mice evaluated by histology (regardless of p53 status) demonstrated 
some degree of spongiform change in either the hippocampus, near the lateral ventricles 
or in the front of the cortex, including the caudate putamen (data not shown). This 
evaluation only included euthanized and perfused mice, and did not include mice which 
were found dead and therefore had probable degradation between death and when the 
brains were dissected. Interestingly, these spongiform changes were not observed in 
any of the P4 week-treated Nestin-CreER/IDH2R172K/wt mice, regardless of p53 status. 
Our X-gal studies have identified that E18.5-treated mice have a greater fraction of cells 
expressing mutant IDH2 than P4-week treated mice. The areas with spongiform change 
appear to correlate with the areas of highest numbers of positive cells. It is tempting to 
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speculate that this may reflect a degree of 2-HG-related neurotoxicity within the E18.5-
treated Nestin-CreER/IDH2R172K/wt mice. Interestingly, one study in patients comparing 
GBMs with and without mutant IDH1 found that tumors with IDH1R132H/wt were more likely 
to have a cystic component and be in contact with the ventricles than tumors with wild-
type IDH1.168 Directed studies correlating 2-HG levels and degree of spongiform change 
within the same brain are needed to verify these intriguing observations. This also 
provides a possible explanation for the decrease in survival observed among E18.5-
treated Nestin-CreER/IDH2R172K/wt mice, and for the lack of obvious tumors in the 
majority of brains assessed by histology. If IDH2R172K induced in neural stem cells 
present at E18.5 leads to neurotoxicity, this could decrease the lifespan of impacted 
mice. 
 
6.3.2. Mouse Models and Tumors 
 
To better study the role of mutant IDH2 in brain tumors, we expressed the mutant 
protein in a select population of neural stem cells and their progenitors. The cells 
induced were either 1) E18.5 neural stem cells and their progenitors, or 2) P4-week 
neural stem cells and their progenitors. Since p53 is also frequently mutated in 
progressive gliomas, we also induced heterozygous or homozygous deletion of p53 
utilizing the same driver. No tumors were noted in mice with only mutant IDH2, 
regardless of when they were treated with tamoxifen. This would suggest the possibility 
that IDH2R172K is at most weakly oncogenic, and not sufficient to lead to tumor formation 
in this model system. However, it is possible that we are not reaching the correct cell-of-
origin, in which it might more rapidly form tumors. Thus, mouse studies utilizing different 
Cre drivers, such as GFAP-CreER (which would lead to induction of mutant IDH2 in 
  90 
GFAP positive cells only following treatment with tamoxifen), or treatment with tamoxifen 
at different time points in either CreER system, may help clarify this further. 
Tumors were identified in E18.5-treated mice that had IDH2 mutation and 
simultaneous deletion of p53. One mouse developed a tumor encompassing a large 
central portion of the brain. Two mice developed flank tumors; one of these mice was 
also found incidentally to have a tumor in the olfactory bulb. However, these tumors did 
not all share the histological features typically associated with astrocytomas or 
oligodendrogliomas. Further studies are needed to better characterize these tumors. 
Additionally, it is extremely challenging to draw large conclusions based on such a small 
number of tumors. These studies provide a base upon which to build our understanding 
of mutant IDH2 and progressive gliomas. The expansion of the number of mice with 
these genotypes may help us better understand these tumors by giving us a larger 
number to explore and characterize. 
Genetically-engineered mouse model systems for the study of gliomas rarely 
demonstrate formation of tumors in the setting of only one genetic alteration. Mutations 
in IDH2 and p53 are not the only mutations observed in progressive gliomas. Further 
information on the roles of mutations in the development and progression of tumors may 
be yielded through the introduction of other commonly observed mutations in both 
progressive astrocytomas and oligodendrogliomas. These include alterations such as 
PDGFR overexpression, oncogenic PIK3CA mutation, or deletion of Rb, ATRX, ARF, 
CIC, or FUBP1. These studies will provide us not only with an insight into the impact 
different mutations have on the progression of gliomas, but also have the potential to 
provide unique, genetically-faithful model system in which to test therapies against this 
devastating disease. 
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Appendix A 
 Section 3 is based on an article published in Biochemical and Biophysical 
Research Communications. Per the journal at 
http://www.elsevier.com/wps/find/authorsview.authors/rights, the rights of the authors 
include “the right to include the journal article, in full or in part, in a thesis or dissertation.” 
For Section 4.2.5 and 4.3.5, which are in part from work in Koivunen, et al., Nature, 
2012, data or protocols from that article were included based on the rights of authors as 
described in http://www.nature.com/reprints/permission-requests.html to “reproduce the 
Contribution in whole or in part in any printed volume (book or thesis) of which they are 
the author(s),” as long as the journal is acknowledged and referenced. 
For Section 1, portions of that section are based on a review (López, G. Y., 
Cummings, T. J., Bigner, D. D. and McLendon, R. E. 2011. Brain Tumours. eLS.). 
Permission was received from Wiley for use of the material for this thesis. 
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Appendix B 
 
 
Figure  B-­‐‑  1:  Measurable  increase  in  2-­‐‑HG  in  cell  lysates  following  exposure  of  
wild-­‐‑type  mouse  ES  to  2-­‐‑HG  in  cell  culture  media.  
 
 
Figure  B-­‐‑  2:  Glutamine  is  decreased  in  mouse  ES  cells  with  mutant  IDH1/2.    
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Figure  B-­‐‑  3:  2-­‐‑aminobutyrate  is  increased  in  mouse  ES  cells  with  mutant  IDH1/2.  
 
 
 
Figure  B-­‐‑  4:  5-­‐‑methylcytosine  is  not  significantly  changed  in  mouse  ES  cells  with  
mutant  IDH1/2.  
                                                         Each  
value  represents  measurements  from  five  biological  replicates.  Error  bars  represent  
standard  deviation.  Difference  from  control  was  P<0.05  for  IDH1  B9,  IDH1  C6,  and  IDH2  
C5.  
                                                        
        Studies  were  completed  in  duplicate.  Error  bars  represent  standard  
deviation.  
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Figure  B-­‐‑  5:  Survival  among  E18.5-­‐‑treated  and  P4-­‐‑week-­‐‑treated  mice.  
 
 
 
Figure  B-­‐‑  6:  Survival  in  P4-­‐‑week-­‐‑treated  mice.  
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Figure  B-­‐‑  7:  Immunohistochemistry  on  A,B)  olfactory  bulb  tumor  or  C,D)  flank  
tumor  in  E18.5-­‐‑treated  Nestin-­‐‑CreER/IDH2R172K/wt/p53fl/fl  mouse. 
 
 
 
Figure  B-­‐‑  8:  Immunohistochemical  stains  on  flank  tumor  from  E18.5-­‐‑treated  
Nestin-­‐‑CreER/IDH2R172K/wt/p53fl/fl  mouse.  
  
  
B"A"
C" D"
A" B"
A,C)  GFAP  staining,  
B,D)  S-­‐‑100  staining.  
A)  GFAP  stain,  B)  S-­‐‑100  stain.  
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